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ABSTRACT 
 
Bacterial infections were the major cause of death and morbidity prior to the 
development of modern antibiotics, and the increasing resistance of pathogenic 
bacteria to commonly used antibacterial agents is a major public health concern. 
During our efforts to develop transition-state analog inhibitors for bacterial cell wall–
synthesizing enzymes, we observed that D-boroAlanine (D-Ala with the -COOH 
group replaced with a -B(OH)2 group) had effective antibacterial activity. In the first 
part of this dissertation, we describe the antibacterial properties of D-boroAla, 
structure–activity correlation among several D-boroAla homologs, and determination 
of the biochemical mechanism for D-boroAla’s antibacterial activity. This study 
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demonstrates that D-boroAla has broad-spectrum antibacterial activity and targets D-
Ala-D-Ala ligase (DDL) in the alanine branch of bacterial cell wall biosynthesis. 
Vancomycin exerts its antibacterial effect by binding to the D-Ala-D-Ala 
termini of pentapeptide peptidoglycan precursors, thereby interfering with the last 
steps of bacterial cell wall biosynthesis. In the most clinically common resistance 
mechanisms in VRE, the terminal D-Ala-D-Ala moiety of peptidoglycan precursors is 
replaced by D-Ala-D-Lac. The middle section of the dissertation deals with 
developing an LC-MS/MS assay for detection and quantitation of D-Ala-D-Lac, the 
key intermediate for most types of vancomycin resistance. This assay was validated 
and then used to demonstrate the effect of vancomycin induction on alanine branch 
metabolites – including D-Ala-D-Lac, in VRE. 
Considerable research has been done on the synthesis of peptides and 
peptide mimetics using classical solid-phase peptide synthesis (SPPS) in the 
classical C-to-N direction. However, this strategy is not generally useful for preparing 
C-terminally modified peptide derivatives, which are of high interest as bioactive 
agents and drugs. SPPS in the N-to-C direction inverse SPPS (ISPPS) would 
provide the synthetically versatile C-terminal carboxyl group for further elaboration. 
Prior studies in our laboratory established the feasibility of performing ISPPS using 
readily available amino acid OtBu esters. In the last section of this dissertation, 
described efforts to develop a backbone amide attachment linkers with the 
appropriate chemical stability for ISPPS i.e. stable to 25% TFA/DCM treatment and 
cleavable with 5% HBr/TFA. Candidate linkers were then loaded onto 
aminomythylated polystyrene resin to demonstrate an effective method for ISPPS 
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using amino acid t-butyl esters. Chemical sensitivity to different capping groups on 
sensitivity to cleavage was demonstrated and several tripeptides were synthesized 
using this approach. 
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CHAPTER 1 
INTRODUCTION 
Bacteria are single celled microscopic organisms. They are one of the oldest 
living organisms on earth and are omnipresent. Bacteria are abundantly present in 
the air we breathe, the food we eat, the water we drink, the human body, plants, 
animals, and the surfaces we touch. There is virtually no place on earth without the 
presence of bacteria. 
Most people have the prejudice that bacteria are always harmful, but only 1% 
are harmful. Early in the 20th century, Elli Metchnikoff, a Russian Nobel laureate, 
discovered that some bacteria present in our bodies are useful in several internal 
processes. These bacteria are called ‘probiotics’. Examples of good and bad 
bacteria are given below. 
Good bacteria 
Lactobacilli species are found in the mouth, intestine and vagina of humans 
and animals and are also present in milk, dairy products and fermented foods. They 
convert sugar and lactose into lactic acid.  They are used in preparation of 
fermented foods, and yogurt from milk. They are known to relieve lactose 
intolerance, gastrointestinal problems, and vaginal yeast infections in mammals. 
Bifidobacterium present in the gastrointestinal tract of humans prevents the growth 
of pathogenic bacteria in the intestine by altering the pH levels upon production of 
lactic acid. Escherichia coli (E. coli) is present in small and large intestines, and 
helps in digestion by breaking down of monosaccharide sugars. They are also 
known to produce vitamin K and biotin which are vital nutrients. Streptomyces 
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present in soil, water and decaying matter are useful in decomposing the organic 
matter present in soil. Several bacterial species like Rhizobium etli, Azorhizobium 
spp, Bradyrhizobium spp, and many others are useful in fixing nitrogen from the 
atmosphere and convert it into usable compounds for plants. Methanotrophs 
metabolize the greenhouse gas methane. Alcanivorax feeds on petroleum, and is 
used in cleaning petroleum spills. 
Bad bacteria 
Enterococci bacteria are often found in human intestines and the female 
genital tract are naturally resistant to many antibiotics and cause systemic infections. 
Vancomycin is the drug of choice to treat infections caused by enterococci. 
Vancomycin-resistant enterococci, first reported in late 1980s [1], are now 
widespread and can cause infections to the urinary tract, bloodsteam and wounds 
associated with catheters or surgical procedures [2]. Staphylococcus aureus, 
frequently found in the human respiratory tract and on the skin, can cause skin 
infections, respiratory disease and food poisoning. Methicillin-resistant 
Staphyloccoccus aureus (MRSA) is a strain of S. aureus that is resistant to many β-
lactam antibiotics. In a hospital setting MRSA can cause life threatening bloodstream 
infections, pneumonia and surgical site infections. Typhoid fever common in the 
developing countries is caused by bacterium salmonella Typhi. Each year around 
21.5 million people are affected by typhoid fever. E. coli normally live in the human 
as well as animal intestine and are usually harmless. But certain strains of E. coli 
can cause diarrhea, urinary tract infections, respiratory illness and pneumonia. 
Shigellosis is an infectious disease caused by a group of bacteria called shigella. 
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People infected with shigella develop diarrhea, fever and stomach cramps. P. 
aeruginosa is one of the most common Gram-negative bacteria found in nosocomial 
infections and can cause infections of the blood, skin, eye, gut, respiratory and 
genitourinary tract in patients suffering from AIDS, cancer, surgery, cytotoxic drugs 
or burn wounds [3]. Infections caused by P. aeruginosa kill several thousand 
individuals each year and 10% of all hospital acquired nosocomial infections are 
accounted to P. aeruginosa [4]. Melioidosis, also known as Whitmore’s, disease is 
caused by the bacterium Burkholderia pseudomallei. Common symptoms include 
pain in chest, bones, or joints, cough, skin infections and pneumonia. 
Bacteria Classification  
Bacteria taxonomy was started by Ferdinand and Cohn in 1872 and classified 
bacteria as members of plants based upon their morphology [5]. Besides 
morphology, growth requirements and pathogenic potential became the most 
important taxonomic markers between 1880 and 1900 [5]. The history of the 
classification of bacteria changed with the availability of new techniques. 
Physiological and biochemical data were used, along with morphology for the 
classification and identification between 1900 and 1960. In the later years chemo 
taxonomy, numerical taxonomy, DNA-DNA hybridization, genotypic analysis, 
multilocus sequence analyses, average nucleotide identity, and whole genome 
analysis were used as markers for the classification of bacteria [6-11]. 
Of all the classification systems, the Gram stain technique developed by H.C. 
Gram in 1884 remains an important and useful technique to this day. It classifies a 
large proportion of bacteria as either Gram positive or negative based on their 
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differential staining properties. In this technique bacteria are stained with crystal 
violet and iodine, and then washed and counter-stained with safranin red dye.  Gram 
positive bacteria retain the original crystal violet stain and Gram negative bacteria 
lose the crystal violet stain during washing step and will retain the counterstain 
safranin red [12]. Gram positive bacterial cell walls consists of a thick layer of 
peptidoglycan that holds teichoic and lipoteichoic acids. Gram negative bacterial cell 
walls consists of a thin layer of peptidoglycan and an outer membrane that 
comprises lipopolysaccharide, phospholipids and proteins. The periplasmic space 
between the cytoplasmic and outer membranes holds transport, degradative, and 
cell wall synthetic proteins. The outer membrane is attached to the peptidoglycan by 
lipoprotein links and is joined to the cytoplasmic membrane at adhesion points 
Figure 1. The difference in retaining stains is mainly due to the difference in the 
peptidoglycan layer in the cell wall structure of the bacteria. 
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Figure 1. A) Gram Postive bacterial cell wall; B) Gram negative bacterial cell wall. 
adapted from micro.digitalproteus.com 
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History of antibacterial agents 
Van Leeuwenhoek’s invention of the microscope in 1670s lead to the 
identification of the first bacteria. The possibility that bacteria might be responsible 
for disease was widespread in nineteenth century after Pasteur demonstrating that 
specific bacterial strains were crucial for fermentation [13]. This possibility became a 
fact in latter half of the nineteenth century, when scientists such as Koch were able 
to identify the bacteria responsible for diseases such as tuberculosis, cholera, and 
typhoid. This led to efforts to find effective antibacterial agents. Paul Ehrlich who 
won a Nobel prize for his contribution to immunology, later changed his area of 
research to a new area which he defined as chemotherapy. Ehrlich’s ‘Principle of 
Chemotherapy’ popularly known as the ‘magic bullet’, was that specific chemical 
bullets which could destroy the microorganism without adversely affecting the host. 
By 1910, Ehrlich successfully developed first synthetic antimicrobial drug Salvarsan, 
an arsenic-containing compound used to treat syphilis. Over the next two decades 
efforts in finding antibacterial agents were futile, until the introduction of proflavine in 
1934. Proflavine is a yellow colored aminoacridine structure effective against 
bacterial infections in deep surface wounds. Although proflavine was successful in 
treating certain kind of bacterial infections but was not effective against bacterial 
infections in bloodstream, urgent need was there to find agents that could fight these 
kind of infections. A red dye called prontosil was discovered in 1935 and found to be 
effective against streptococal infections in vivo. Later it was recognized as a prodrug 
to a new class of antibacterial agents sulfonamides. These were effective against 
bacterial infections carried in the bloodstream, and were the only available drugs 
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until penicillin became available in early 1940s. Although Fleming discovered 
penicillin in 1928, an effective means of isolating it was developed only in 1940 by 
Florey & Chain. This revolutionized the fight against bacterial infection, and was 
even more effective than sulfonamides. Despite penicillin’s success, it was not 
effective against all types of infections and the need for new antibacterial agents still 
remained. Streptomycin, the first example of series of antibiotics known as the 
aminoglycoside antibiotics was discovered from soil organisms in 1944. Efforts to 
find new antibiotics led to the discovery of series of antibiotics, such as bacitracin a 
peptide antibiotic in 1945, chloramphenicol in 1947, chlortetracycline a tetracycline 
antibiotic in 1948, erythromycin a macrolide antibiotic in 1952, cycloserine a cyclic 
peptide antibiotic in 1955, cephalosporin C a second major group of β-lactam 
antibiotics in 1955, and vancomycin a glycopeptide in 1956. Synthetic agents such 
as isoniazid a pyridine hydrazide structure, and nalidixic acid the first quinolone 
antibacterial agent, were discovered in 1952 and 1962 respectively [13].  
From 1960s to 2000, all antibiotics approved for clinical use were synthetic 
derivatives of existing scaffolds. Around 73% of antibacterial agents, new chemical 
entities filed between 1981 and 2005 are just from four scaffolds - cephalosporins, 
penicillins, quinolones, and macrolides [14]. Around 20 new classes of antibiotics 
were identified between 1930 and 1960, but since then only three new classes of 
antibiotic oxazolidinones, lipopeptides, and mutilins, were developed Figure 2 [15-
19]. Antibiotics and their respective analogues that are developed so far are listed in 
Figure 3. Analogue development was more successful for cephalosporins, pencillins 
and quinolones as there are sites in the scaffolds for easy modification [20]. 
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Eventually analogue development based on the core structure will becomes too 
difficult or too expensive to make especially with new antibiotic resistance 
mechanisms. So there is an urgent need for development of new class of 
antibacterial agents that act by novel mechanisms and for which mechanisms of 
resistance are not yet known [21]. 
 
 
 
Figure 2. Timeline of antibiotic classes inventions. Adapted from M.A. Fischbach and 
C.T.Walsh 2010. 
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Figure 3. Main classes of marketed antibiotics. Adapted from A.R. Coates et. al. 
2011. 
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Mechanism of action of antibacterial agents 
Antibacterial agents act selectively on vital bacterial functions with nominal 
effects or without affecting host functions. The mechanism of action of antibacterial 
agents can be categorized based on how they affect the bacterial physiology or 
biochemistry Figure 4. There are five general modes of action: 
1) Inhibition of cell wall synthesis 
2) Inhibition of protein synthesis 
3) Inhibition of nucleic acid synthesis 
4) Inhibition of folate metabolism  
5) Inhibition of cell membrane function 
Antibacterial agents that inhibit cell wall synthesis include β-lactams, such as 
penicillins, cephalosporins, carbapenems, monobactams, and glycopeptides, such 
as vancomycin and teicoplanin [22-23]. β-lactams interfere with the enzymes 
required for the synthesis of peptidoglycan layer thereby inhibiting the synthesis of 
the bacterial cell wall [22]. Glycopeptides binds to the terminal D-alanine residues of 
the nascent peptidoglycan chain, thereby inhibiting the cross-linking steps required 
for cell wall synthesis [22].  
Antibacterial agents that inhibit protein synthesis include aminoglycosides, 
tetracyclines, macrolides, chloramphenicol, streptogramins, and oxazolidinones [22-
23]. Aminoglycoside and tetracyclines bind to the 30s subunit of the ribosome, 
whereas macrolides, chloramphenicol, and clindamycin binds to the 50s subunit 
[24].  
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Figure 4. Antibiotic targets and mechanisms of resistance. Adapted from G.D. Wright 
2010. 
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Fluoroquinolones exert their antibacterial affects by slelectively inhibiting 
topoisomerase ligase domain causing DNA fragmentation during DNA replication 
[25]. Rifamycins exert their antibacterial activity by selectively binding to bacteria’s 
RNA polymerase there by blocking RNA synthesis [26-27].  
Sulfonamides and trimethoprim exert their antibacterial activity by inhibiting two 
enzymatic steps dihydropteroate synthetase and dihydrofolate reductase 
respectively, thereby inhibiting the synthesis of folic acid, an important metabolite in 
DNA synthesis. Trimethoprim, a folic acid analogue plus, sulfamethoxazole, a para-
aminobenzoic acid (PABA) analogue, are used in combination for their synergistic 
effects. They inhibit in the bacterial folate synthesis pathway [28-29]. 
Polymyxins exert their inhibitory effects by binding to lipopolysaccharide (LPS) 
present on the outer membrane of Gram-negative bacteria, causing membrane 
damage and leakage of bacterial contents [30]. Daptomycin a cyclic lipopeptide 
exerts its antibacterial activity by inserting its lipid tail into the bacterial cell 
membrane, causing rapid membrane depolarization and eventual death of the 
bacterium [31]. 
Bacteria Resistance mechanisms to antibiotics 
The four main mechanisms by which bacteria exhibit resistance to 
antibacterial agents are inactivating enzymes, target modification, alteration of 
metabolic pathway, and efflux. The major mechanism of β-lactam resistance is due 
to enzyme mediated antibiotic degradation. Three classes of enzymes namely β-
lactamases, acylases, and esterases hydrolyze β –lactam antibiotics resulting in 
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degradation of β –lactam nucleus [32-34]. Aminoglycoside resistance is due to 
enzyme mediated antibiotic modification. Aminoglycoside-modifying enzymes 
inactivate aminoglycoside antibiotics by catalyzing acetylation, nucleotidylation or 
phosphorylation reactions at either amino or hydroxyl groups on aminoglycoside 
antibiotics [35-38]. Similarly chloramphenicol acetyltransferase inactivates 
chloramphenicol by acetylation [39-41]. In vancomycin-resistant enterococcus, 
resistance to vancomycin was achieved by replacing the terminal D-Ala-D-Ala 
moiety of peptidoglycan precursors with D-Ala-D-Lac [42-43]. Bacteria developed 
resistance to trimethoprim either by producing an altered dihydrofolate reductase 
that lacks the capacity to bind trimethoprim or by over producing the normal 
dihydrofolate reductase, the latter is particularly in E. coli and Klebsiella pneumonia 
[44-49]. Sulfonamides resistance was due to the production of plasmid-encoded 
dihydropteroate synthetase which has a decreased affinity for sulfonamides [48, 50-
51]. Macrolide resistance is either due to post-transciptional methylation of the 23S 
ribosomal RNA or production of active ATP-dependent efflux proteins that transport 
drug outside of the cell [52-53]. Tetracycline resistance is either due to ribosomal 
protection proteins that dislodge tetracycline form the ribosome and allowing the 
translation or due to efflux pumps that transport the tetracycline outside of the cell 
[54-56]. 
Some strains of bacteria have developed resistance to all commonly available 
agents. Among gram positive strains methicillin resistant Staphylococcus aureus 
(MRSA) needs a special mention. MRSA is not only resistant to methicillin but 
usually also to aminoglycosides, macrolides, tetracycline, chloramphenicol, and 
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lincosamides [57]. Among gram negative strains multidrug-resistant 
carbapenemase-producing Klebsiella pneumonia, Pseudomonas aeruginosa, 
Burkholderia sp. and Acinetobacter spp. developed resistance to all currently 
available antibacterial agents or remain susceptible to potentially more toxic agents 
such as the polymyxins [58-60]. These bacteria have developed resistance by 
accumulation of resistance plasmids or transposons, of genes with each coding for 
resistance to specific agent, and/or by multidrug efflux pumps, which can pump out 
more than one drug type [57]. 
We are totally dependent on antibiotics for the treatment of infectious 
diseases. Antibiotics are also critical for the success of many surgical procedures. 
Resistant bacteria have created an enormous clinical and financial burden on health 
care systems. At present it seems likely that bacteria resistant to essentially all the 
commonly used antibiotics will soon emerge. Further heightening concern about 
existing and emerging bacterial drug resistance is the fact that, only three new class 
of antibacterial agents have been introduced into clinical practice in the last 
50 years. Therefore, there is an urgent need to identify new classes of antibacterial 
agents, especially agents that act through novel mechanisms and for which 
mechanisms of resistance are not yet known [21]. 
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CHAPTER 1 
IDENTIFICATION OF D-BOROALA AS A NOVEL ANTIBACTERIAL AGENT 
Penicillin-binding proteins (PBPs) [61] are ubiquitous bacterial enzymes 
whose physiological function is to form and modulate the crosslinks important to 
bacterial cell wall integrity [61-64]. PBPs can be broadly divided into two groups: the 
low molecular mass (LMM) PBPs with molecular mass ranging from 20-50 kDa, and 
the high molecular mass (HMM) PBPs with molecular mass ranging from 50-120 
kDa. In most Gram negative bacteria the reactions catalyzed by the PBPs are shown 
in Figure 5.  
 
~L-Ala-D--Glu-L-Lys-D-Ala-D-Ala
NH
PBP-Ser-OH D-Ala
~L-Ala-D--Glu-L-Lys-D-Ala
NH
Cell Wall Pentapeptide Acyl Enzyme Intermediate
PBP-Ser-OH
~L-Ala-D--Glu-L-Lys-D-Ala
NH
Hydrolase Product
~L-Ala-D--Glu-L-Lys-D-Ala~
NH2
O
O-Ser-PBP
~L-Ala-D--Glu-L-Lys-D-Ala
NH
O
~L-Ala-D--Glu-L-Lys-D-Ala~
NH2
Transpeptidase Product
(Crosslinked)
PBP-Ser-OH
H2O
OR
 
Figure 5. Bacterial cell wall biosynthesis reactions catalyzed by the PBPs in most 
Gram negative bacteria. Adapted from Bobba et. al. 2011. 
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The active site serine of the PBPs reacts with the D-Ala-D-Ala moiety, its 
pentapeptide substrate to form an acyl-enzyme complex, releases the C-terminal D-
Ala. This acyl-enzyme intermediate can then either undergo hydrolysis resulting in a 
tetrapeptide (carboxypeptidase product) or transpeptidation by forming a cross link 
with amino group of another pentapeptide (transpeptidase product). The cross linked 
product can also be cleaved by PBPs (endopeptidase activity). 
The active site serine involved in the acyl transfer reaction is the target of the 
β-lactam antibiotics, which inhibit the PBPs by acting as substrate analogs of D-Ala-
D-Ala to form a stable acyl enzyme complex resistant to subsequent hydrolysis [65-
67]. Bacteria were developed resistance to β-lactam antibiotics primarily by two 
mechanisms: producing β-lactam hydrolyzing enzymes known as β-lactamases [68], 
and acquiring mutations in their HMM PBP targets that make them less susceptible 
to β-lactam antibiotics [63, 69].  
Transition state analogues (TSAs) are compounds that mimic the transition 
state of enzyme-catalyzed reactions and are the potent inhibitors for that particular 
enzyme [70-71]. There are several well-known classes of such inhibitors for the 
serine proteases, including peptide chloromethyl ketones [72-73], peptide boronic 
acids [74-75], peptide aldehydes [76], and peptide tri- and di-fluoromethyl ketones 
[77-78]. In an effort to combat β-lactam resistant bacteria, TSAs have been 
developed for β-lactamases, including boronic acids [79-83], and phosphonates [84-
86], but potent inhibitors have not emerged from these studies [87]. 
In an effort to develop new non β-lactam inhibitors for the PBPs that could 
provide a basis for new antibacterial agents, a series of potential TSA inhibitors for 
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the PBPs were synthesize in our lab [88]. The classes of agents synthesized were 
peptide aldehydes, peptide trifluoromethyl ketones, peptide chloromethyl ketones, 
and peptide boronic acids Figure 7. These compounds were tested as inhibitors 
against a set of LMM PBPs: Escherichia coli (EC) PBP 5, Neisseria gonorrhoeae 
(NG) PBP 3, and NG PBP 4. Peptide boronic acids were found to be the most 
effective in the series of compounds synthesized. The lowest KI of 370 nM was 
obtained for NG PBP 3 inhibition by Boc-L-Lys(Cbz)-D-boroAla. These compounds 
were subsequently tested for their antibacterial activity using filter disc assays. It was 
observed that Boc-L-Lys(Cbz)-D-boroAla had antibacterial activity. However, the 
antibacterial activity observed in different preparations was variable. The crude 
compound was resolved on a TLC plate, and the TLC plate was tested for 
antibacterial activity. Two halos were observed on the petri dish, one at the top of 
the plate, and the other at the bottom of the plate Figure 6. The halo at the bottom of 
the TLC plate is much bigger than that at the top. We identified that the compound at 
the bottom of the TLC as D-boroAla by running all the reagents used for the reaction, 
crude Boc-L-Lys(Cbz)-D-boroAla, and purified Boc-L-Lys(Cbz)-D-boroAla on TLC. 
This identified D-boroAla as the active compound, pure D-boroAla was tested for 
antibacterial activity using filter disc assay, and confirmed as the active agent Figure 
6.  
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Figure 6. TLC of crude Boc-L-Lys(Cbz)-D-boroAla and the zone of inhibition of the 
TLC resolved compounds on S. aureus. 
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Figure 7. Transition state analogues synthesized in our lab. Adapted from Pechenov 
et., al 2003. 
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Figure 8. Substrate specificity and corresponding transition state analogues for 
serine proteases and related enzymes. The four transition state analogue classes 
shown at the bottom can form tetrahedral adducts with the active site serine. 
Adapted from Pechenov et., al 2003. 
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CHAPTER 2 
CHARACTERIZATION OF D-BOROALA AS A NOVEL BROAD-SPECTRUM 
ANTIBACTERIAL AGENT TARGETING D-ALA-D-ALA LIGASE. 
Introduction and Rationale  
Bacterial infections were the major cause of death and morbidity prior to the 
development of modern antibiotics, and the increasing resistance of pathogenic 
bacteria to commonly used antibacterial agents is of major public health concern. 
Methicillin-resistant Staphylococcus aureus (MRSA) and several Gram-negative 
pathogens such as Pseudomonas aeruginosa, Burkholderia sp., Acinetobacter 
baumannii, and Klebsiella pneumoniae are of particular concern [21, 89-94]. Further 
heightening concern about existing and emerging bacterial drug resistance is the 
fact that, although a number of new antibacterial agents from known antibacterial 
classes are under development, only two new class of antibacterial agents have 
been introduced into clinical practice in the last 40 years – the oxazolidinones as 
represented by linezolid [95] and the lipopeptides as represented by daptomycin [96-
97]. There is therefore an urgent need to identify new classes of antibacterial agents, 
especially agents that act through novel mechanisms and for which mechanisms of 
resistance are not yet known [21]. 
During our efforts to develop transition-state analog inhibitors for bacterial cell 
wall–synthesizing enzymes [88, 98], we observed that D-boroAlanine (D-Ala with the 
-COOH group replaced with a -B(OH)2 group) had effective antibacterial activity. 
While D-boroAla has previously been described as an inhibitor of alanine racemase 
and D-Ala-D-Ala ligase (DDL) [99], it has not previously – to our knowledge – been 
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reported as an antibacterial agent. In this report, we describe the antibacterial 
properties of D-boroAla, structure–activity correlation among several D-boroAla 
homologs, and determination of the biochemical mechanism for D-boroAla’s 
antibacterial activity. This study demonstrates that D-boroAla has broad-spectrum 
antibacterial activity and targets DDL in the alanine branch of bacterial cell wall 
biosynthesis Figure 9. 
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Figure 9. Bacterial cell wall biosynthesis pathway in E.Coli. Adapted from Jamindar  
et. al. 2009. 
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Materials and Methods 
General: D-Ala, L-Ala, D-Ala-D-Ala, 13C3-D-Ala, D-cycloserine, and ampicillin 
were purchased from Sigma–Aldrich (St. Louis, MO, USA). C18 silica gel was 
obtained from Sep-Pak Cartridges (Waters, Milford, MA, USA). Marfey’s reagent (1-
fluoro-2,4-dinitripheny-L- 5-alanine amide) was purchased from Novabiochem (a 
division of EMD Chemicals, Gibbstown, NJ, USA). Other reagents were obtained 
from standard sources and were reagent grade or better. M9 minimal medium, 
consisting of Na2HPO4 (6 g/L), KH2PO4 (3 g/L), NH4Cl (1 g/L), NaCl (0.5 g/L), 
MgSO4x7H2O (1 mM), FeSO4x7H2O (3 mg/L), vitamin B1 (thiamine, 0.5 mg/L), and 
glycerol (20%, as carbon source), was prepared following standard procedures. LC–
MS/ MS was performed on an Applied Biosystems Sciex (ABI) 2000 QTrap LC–
MS/MS mass spectrometer equipped with an Agilent 1100 HPLC system. All 
chromatographic separations ware performed on a Nucleodur 100-3 C8 column (125 
x 2.0 mm, Macherey–Nagel, Bethlehem, PA, USA). All centrifuge operations were 
performed on a Sorvall RT 6000 refrigerated centrifuge. Minimum inhibitory 
concentration (MIC) measurements were performed in 96-well microtiter plates and 
read with a Tecan Spectrafluor Plus spectrofluorometer. Klett measurements of 
cultures were performed at 600 nm using a BioMate 3 Thermo Spectronic 
spectrometer.  
Compound Synthesis 
General. The synthesis strategy used for alkyl side chain D-boro-amino acid 
analogs, adapted from the general procedure describe for L-boro analogs as 
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described by Matteson, Kettner, and coworkers [99-101]; is outlined in  Figure 10 
and Figure 11. 
  Diisopropyl-(1-methyl)-1-borate (1a): Triisopropylborate (160 mmol, 30 g) was 
dissolved in 500 mL of dry ether cooled to – 72 oC in an isopropanol/dry ice bath. 
Methyl lithium (160 mmol, 100 mL) was added slowly over a 30 min period, and the 
reaction left to warm to room temperature overnight. The reaction mixture was 
cooled to 0 oC and quenched with 1 M HCl in ether (160 mmol). The precipitate was 
removed by filteration, the ether distilled off and the product is collected by 
distillation at atmospheric pressure at 110 oC. The yield was 13.6 g (59%) of product 
as a clear oil. 1H NMR (400 MHz, CDCl3): δ 4.41-4.31 (Heptet, J=6.15 Hz, 2 H), 
1.18-1.15 (d, J=5.89 Hz, 12H), 0.24 (s, 3H) Figure 20. 
Diisopropyl-(1-ethyl)-1-borate (1b): Triisopropylborate (160 mmol, 30 g) was 
dissolved in 500 mL of dry ether cooled to – 72 oC in an isopropanol/dry ice bath. 
Ethyl lithium (160 mmol, 100 mL) was added slowly over a 30 min period, and the 
reaction left to warm to room temperature overnight. The reaction mixture was 
cooled to 0 oC and quenched with 1 M HCl in ether (160 mmol). The precipitate was 
removed by filteration, the ether distilled off and the product is collected by 
distillation at atmospheric pressure at 230 oC. The yield was 15.4 g (61%) of product 
as a clear oil. 1H NMR (400 MHz, CDCl3): δ 4.39-4.29 (Heptet, J=6.55 Hz, 2H), 1.16-
1.14 (d, J=5.72 Hz, 6H), 1.14-1.11 (d, J=6.06 Hz, 6H), 0.94-0.89 (T, J=7.77 Hz, 3H), 
0.76-0.68 (Q, J=7.44 Hz, 2H) Figure 21. 
Diisopropyl-(1-isopropyl)-1-borate (1c): Triisopropylborate (160 mmol, 30 g) 
was dissolved in 500 mL of dry ether cooled to – 72 oC in an isopropanol/dry ice 
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bath. Isopropyl lithium (160 mmol, 100 mL) was added slowly over a 30 min period, 
and the reaction left to warm to room temperature overnight. The reaction mixture 
was cooled to 0 oC and quenched with 1 M HCl in ether (160 mmol). The precipitate 
was removed by filteration, the ether distilled off and the product is collected by 
distillation at atmospheric pressure at 175-184 oC. The yield was 14.1 g (51%) of 
product as a clear oil. 1H NMR (400 MHz, CDCl3): δ 4.39-4.29 (Heptet, J=6.55 Hz, 
2H), 1.16-1.14 (d, J=5.72 Hz, 6H), 1.14-1.11 (d, J=6.06, 6H), 1.02-0.99 (d, J=6.85 
Hz, 6H), 0.94-0.89 (T, J=7.77 Hz, 3H), 0.76-0.68 (Q, J=7.44 Hz, 2H) Figure 22. 
(-)-Pinanediol-(1-methyl)-1-boronate (2a): (1R, 2R, 3S, 5R)-(-)-pinanediol 
(29.36 mmol, 5 g) was dissolved in diisopropyl-(1-methyl)-borate (1a) (24.47 mmol, 
3.53 g) at room temperature and stirred overnight. The reaction mixture was distilled 
at atmospheric pressure and the product was collected at 98 – 103 oC.  The yield 
was 4.2 g (88%) of product as a clear oil. 1H NMR (400 MHz, CDCl3): δ 4.28-4.24 
(dd, J=2.1 Hz, 1H), 2.37-2.29 (m, 1H), 2.26-2.19 (m, 1H), 2.06-2.02 (T, J=4.76 Hz, 
1H), 1.94-1.89 (m, 1H), 1.88-1.82 (dQ, 1H), 1.39 (S, 3H), 1.29 (S, 3H), 0.85 (S, 3H), 
0.29 (S, 3H) Figure 23. 
(-)-Pinanediol-(1-ethyl)-1-boronate (2b): (1R, 2R, 3S, 5R)-(-)-pinanediol 
(29.36 mmol, 5 g) was dissolved in diisopropyl-(1-ethyl)-borate (1b) (24.47 mmol, 
3.87 g) at room temperature and stirred overnight. The reaction mixture was distilled 
at 15 mm of Hg aspirator pressure and the product was collected at 107 – 110 oC.  
The yield was 3.4 g (67%) of product as a clear oil. 1H NMR (400 MHz, CDCl3): δ 
4.28-4.24 (dd, J=2.1 Hz, 1H), 2.37-2.29 (m, 1H), 2.26-2.19 (m, 1H), 2.06-2.02 (T, 
J=4.76 Hz, 1H), 1.94-1.89 (m, 1H), 1.88-1.82 (dQ, 1H), 1.39 (S, 3H), 1.29 (S, 3H), 
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1.14-1.08 (d, J=10.83 Hz, 1H), 1.01-0.94 (Q, J=8.19 Hz, 2H), 0.85 (S, 3H) Figure 
24. 
  (-)-Pinanediol-(1-isopropyl)-1-boronate (2c): (1R, 2R, 3S, 5R)-(-)-pinanediol 
(29.36 mmol, 5 g) was dissolved in diisopropyl-(1-isopropyl)-borate (1c) (24.7 mmol, 
4.25 g) at room temperature and stirred overnight. The reaction mixture was distilled 
at 15 mm of Hg aspirator pressure and the product was collected at 195 – 198 oC.  
The yield was 5.3 g (96%) of product as a clear oil. 1H NMR (400 MHz, CDCl3): δ 
4.28-4.24 (dd, J=2.1 Hz, 1H), 2.37-2.29 (m, 1H), 2.26-2.19 (m, 1H), 2.06-2.02 (T, 
J=4.76 Hz, 1H), 1.94-1.89 (m, 1H), 1.88-1.82 (dQ, 1H), 1.39 (S, 3H), 1.29 (S, 3H), 
1.14-1.08 (d, J-10.83 Hz, 1H), 1.02-0.99 (Q, J=6.85 Hz, 6H), 0.85 (S, 3H) Figure 25. 
(+)-Pinanediol-(1-methyl)-1-boronate (2d): (1R, 2R, 3S, 5R)-(-)-pinanediol 
(29.36 mmol, 5 g) was dissolved in diisopropyl-(1-methyl)-borate (1a) (26.8 mmol, 
3.86 g) at room temperature and stirred overnight. The reaction mixture was distilled 
at atmospheric pressure and the product was collected at 103 – 116 oC.  The yield 
was 4.61 g of product as a clear oil. and the product was collected at 195 – 198 oC.  
The yield was 5.1 g (98%) of product as a clear oil. 1H NMR (400 MHz, CDCl3): δ 
4.28-4.24 (dd, J=2.1 Hz, 1H), 2.37-2.29 (m, 1H), 2.26-2.19 (m, 1H), 2.06-2.02 (T, 
J=4.76 Hz, 1H), 1.94-1.89 (m, 1H), 1.88-1.82 (dQ, 1H), 1.39 (S, 3H), 1.29 (S, 3H), 
0.85 (S, 3H), 0.29 (S, 3H) Figure 26.   
(-)-Pinanediol (1R)-(1-chloroethyl)-1-boronate (3a):  Anhydrous methylene 
chloride (30.24 mmol, 2.75 mL) was placed in 100 mL round bottom flask, freshly 
distilled THF was transferred into the reaction vessel, and the mixture cooled to – 
100 oC using a methanol/nitrogen slush bath.  2.5M n-butyl lithium (23.76 mmol, 9.5 
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mL) solution in hexane was slowly added along the cold walls of the reaction vessel 
using a canula, and the mixture stirred for 10 min. (-)-Pinanediol-(1-methyl)-1-
boronate (2a) (21.6 mmol, 4.185 g) in 20 mL anhydrous ether was slowly added to 
the reaction mixture along the cold walls of the reaction vessel. Anhydrous zinc 
chloride (15.12 mmol, 2.06 g) was dried under high vacuum, and then added to the 
reaction mixture. The reaction mixture was warmed to room temperature overnight. 
75 mL of petroleum ether was added, and the reaction mixture quenched with 40 mL 
of saturated ammonium chloride. The reaction was extracted, with three times with 
ethyl ether, and the organic phase was dried over MgSO4, filtered and rotovap to 
give crude product as an oil. The pure product was collected at 150 – 159 oC by 
distillation at 30 mm of Hg. The yield was 2.5 g (47%) of product as a light yellow oil. 
1H NMR (400 MHz, CDCl3): δ 4.39-4.35 (dd, J=2.1 Hz, 1H), 3.61-3.54 (Q, J=7.64 Hz, 
1H), 3.52-3.32 (m, 1H) 1.6-1.56 (d, J=7.7 Hz, 3H), 1.43 (S, 3H), 1.3 (S, 3H), 1.19-
1.14 (m, 1H), 0.95-0.89 (m, 2H), 0.85 (s, 3H) Figure 27. 
(-)-Pinanediol (1R)-(1-chloro-1-propyl)-1-boronate (3b):  Anhydrous 
methylene chloride (23.04 mmol, 1.5 mL) was placed in 100 mL round bottom flask, 
freshly distilled THF was transferred into the reaction vessel, and the mixture cooled 
to – 100 oC using a methanol/nitrogen slush bath.  2.5M n-butyl lithium (18.1 mmol, 
7.25 mL) solution in hexane was slowly added along the cold walls of the reaction 
vessel using a canula, and the mixture stirred for 10 min. (-)-Pinanediol-(1-ethyl)-1-
boronate (2b) (16.45 mmol, 3.43 g) in 20 mL anhydrous ether was slowly added to 
the reaction mixture along the cold walls of the reaction vessel. Anhydrous zinc 
chloride (15.12 mmol, 2.06 g) was dried under high vacuum, and then added to the 
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reaction mixture. The reaction mixture was warmed to room temperature overnight. 
75 mL of petroleum ether was added, and the reaction mixture quenched with 40 mL 
of saturated ammonium chloride. The reaction was extracted, with three times with 
ethyl ether, and the organic phase was dried over MgSO4, filtered and rotovap to 
give crude product as an oil. The pure product was collected at 166 oC by distillation 
at 18 mm of Hg . The yield was 1.9 g (45%) of product as a clear oil. 1H NMR (400 
MHz, CDCl3): δ 4.28-4.24 (dd, J=2.1 Hz, 1H), 3.46-3.41 (T, J=6.32 Hz, 1H), 3.52-
3.32 (m, 1H) 1.6-1.56 (d, J=7.7 Hz, 3H), 1.43 (S, 3H), 1.3 (S, 3H), 1.19-1.14 (m, 1H), 
0.95-0.89 (m, 2H), 0.85 (s, 3H) Figure 28. 
(-)-Pinanediol (1R)-(1-chloro-1-isobutyl)-1-boronate (3c):  Anhydrous 
methylene chloride (30.24 mmol, 2.75 mL) was placed in 100 mL round bottom flask, 
freshly distilled THF was transferred into the reaction vessel, and the mixture cooled 
to – 100 oC using a methanol/nitrogen slush bath.  2.5M n-butyl lithium (23.76 mmol, 
9.5 mL) solution in hexane was slowly added along the cold walls of the reaction 
vessel using a canula, and the mixture stirred for 10 min. (-)-Pinanediol-(1-
isopropyl)-1-boronate (2c) (24.53 mmol, 5.45 g) in 20 mL anhydrous ether was 
slowly added to the reaction mixture along the cold walls of the reaction vessel. 
Anhydrous zinc chloride (15.12 mmol, 2.06 g) was dried under high vacuum, and 
then added to the reaction mixture. The reaction mixture was warmed to room 
temperature overnight. 75 mL of petroleum ether was added, and the reaction 
mixture quenched with 40 mL of saturated ammonium chloride. The reaction was 
extracted, with three times with ethyl ether, and the organic phase was dried over 
MgSO4, filtered and rotovap to give crude product as an oil. The pure product was 
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collected at 166 oC by distillation at 18 mm of Hg. The yield was 4.5 g (68%)  of 
product as a clear oil. 1H NMR (400 MHz, CDCl3): δ 4.28-4.24 (dd, J=2.1 Hz, 1H), 
3.35-3.32 (d, J=6.34 Hz, 2H), 3.52-3.32 (m, 1H) 1.6-1.56 (d, J=7.7 Hz, 3H), 1.43 (S, 
3H), 1.3 (S, 3H), 1.19-1.14 (m, 1H), 1.02-0.99 (d, J=6.85 Hz, 6H), 0.95-0.89 (m, 2H), 
0.85 (s, 3H) Figure 29.  
(+)-Pinanediol (1S)-(1-chloroethyl)-1-boronate (3d):  Anhydrous methylene 
chloride (33.2 mmol, 2.13 mL) was placed in 100 mL round bottom flask, freshly 
distilled THF was transferred into the reaction vessel, and the mixture cooled to – 
100 oC using a methanol/nitrogen slush bath.  2.5 M butyl lithium (26.07 mmol, 10.43 
mL) solution in hexane was slowly added along the cold walls of the reaction vessel 
using a canula, and the mixture stirred for 10 min. (-)-Pinanediol-(1-methyl)-1-
boronate (2d) (23.7 mmol, 4.6 g) in 20 mL anhydrous ether was slowly added to the 
reaction mixture along the cold walls of the reaction vessel. Anhydrous zinc chloride 
(15.12 mmol, 2.06 g) was dried under high vacuum, and then added to the reaction 
mixture. The reaction mixture was warmed to room temperature overnight. 75 mL of 
petroleum ether was added, and the reaction mixture quenched with 40 mL of 
saturated ammonium chloride. The reaction was extracted, with three times with 
ethyl ether, and the organic phase was dried over MgSO4, filtered and rotovap to 
give crude product as an oil. The pure product was collected at 160 – 163 oC by 
distillation at 30 mm of Hg. The yield was 3.2 g (56%) of product as a light yellow oil. 
1H NMR (400 MHz, CDCl3): δ 4.39-4.35 (dd, J=2.1 Hz, 1H), 3.61-3.54 (Q, J=7.64 Hz, 
1H), 3.52-3.32 (m, 1H) 1.6-1.56 (d, J=7.7 Hz, 3H), 1.43 (S, 3H), 1.3 (S, 3H), 1.19-
1.14 (m, 1H), 0.95-0.89 (m, 2H), 0.85 (s, 3H)  Figure 30. 
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(-)-Pinanediol (1S)-(1-hexamethyldisilazaneaminoethyl)-1-boronate (4a): 20 
mL of freshly distilled THF over sodium/benzophenone was placed in a round 
bottom flask and cooled to -78 oC using nitrogen/isopropanol slush bath. 1,1,1,3,3,3-
hexamethyl disilazane (11.7 mmol, 2.44 mL) was slowly added along the cold walls 
of the reaction vessel using a canula, then 2.5 M butyl lithium (11.7 mmol, 4.7 mL) 
was added. The reaction mixture was warmed to room temperature for 10 min, then 
cooled to – 78 oC. (-)-Pinanediol (1R)-(1-chloroethyl)-1-boronate (3a) (9.14 mmol, 
2.5 g) was added to the reaction mixture and warmed to room temperature and kept 
the reaction vessel in desiccator for 4 days. THF was distilled off at aspirator 
vacuum and the product was collected at 105 – 115 oC by distillation at 50 µm of Hg. 
The yield was 2.2 g (66%) of product as a light yellow oil. 1H NMR (400 MHz, 
CDCl3): δ 4.32-4.28 (dd, J=1.75 Hz, 1H), 2.76-2.68 (Q, J=8.06 Hz, 1H), 2.36-2.28 
(m, 1H), 2.24-2.16 (m, 1H), 2.06-2.01 (T, J=5.68 Hz, 1H), 1.92-1.87 (m, 1H), 1.87-
1.8 (m, 1H), 1.38 (s, 3H), 1.28 (s, 3H), 1.19-1.16 (d, J=7.91 Hz, 3H), 0.84 (s, 3H), 0.1 
(s, 18H) Figure 31. 
(-)-Pinanediol (1S)-(1-hexamethyldisilazaneamino-1-propyl)-1-boronate (4b): 
20 mL of freshly distilled THF over sodium/benzophenone was placed in a round 
bottom flask and cooled to -78 oC using nitrogen/isopropanol bath. 1,1,1,3,3,3-
hexamethyl disilazane (8.7 mmol, 2.44 mL) was slowly added along the cold walls of 
the reaction vessel using a canula, then 2.5 M butyl lithium (8.7 mmol, 3.5 mL) was 
added. The reaction mixture was warmed to room temperature for 10 min, then 
cooled to – 78 oC. (-)-Pinanediol (1R)-(1-chloro-1-propyl)-1-boronate (3b) (7.25 
mmol, 1.86 g) was added to the reaction mixture and warmed to room temperature 
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and kept the reaction vessel in desiccator for 4 days. THF was distilled off at 
aspirator vacuum and the product is collected at 120 – 139 oC by distillation at 50 
µm of Hg. The yield was 1.1 g (40%) of product as a light yellow oil. 1H NMR (400 
MHz, CDCl3): δ 4.32-4.28 (dd, J=1.75 Hz, 1H), 2.76-2.68 (Q, J=8.06 Hz, 1H), 2.36-
2.28 (m, 1H), 2.24-2.16 (m, 1H), 2.06-2.01 (T, J=5.68 Hz, 1H), 1.92-1.87 (m, 1H), 
1.87-1.8 (m, 1H), 1.79-1.68 (dT, J=7.36 Hz, 2H),  1.38 (s, 3H), 1.28 (s, 3H), 1.19-
1.16 (d, J=7.91 Hz, 3H), 0.84 (s, 3H), 0.1 (s, 18H) Figure 32. 
(-)-Pinanediol (1S)-(1-hexamethyldisilazaneamino-1-isobutyl)-1-boronate (4c): 
20 mL of freshly distilled THF over sodium/benzophenone was placed in a round 
bottom flask and cooled to -78 oC using nitrogen/isopropanol bath. 1,1,1,3,3,3-
hexamethyl disilazane (19.72 mmol, 4.1 mL) was slowly added along the cold walls 
of the reaction vessel using a canula, then 2.5M butyl lithium (19.72 mmol, 7.7 mL) 
was added. The reaction mixture was warmed to room temperature for 10 min, then 
cooled to – 78 oC. (-)-Pinanediol (1R)-(1-chloro-1-isobutyl)-1-boronate (3c) (16.43 
mmol, 4.45 g) was added to the reaction mixture and warmed to room temperature 
and kept the reaction vessel in desiccator for 4 days. THF was distilled off at 
aspirator vacuum and the product is collected at 135 – 145 oC by distillation at 50 
µm of Hg. The yield was 2.1 g (33%) of product as a light yellow oil. 1H NMR (400 
MHz, CDCl3): δ 4.32-4.28 (dd, J=1.75 Hz, 1H), 2.76-2.68 (Q, J=8.06 Hz, 1H), 2.36-
2.28 (m, 1H), 2.24-2.16 (m, 1H), 2.06-2.01 (T, J=5.68 Hz, 1H), 1.92-1.87 (m, 1H), 
1.87-1.8 (m, 1H), 1.38 (s, 3H), 1.28 (s, 3H), 1.19-1.16 (d, J=7.91 Hz, 3H), 1.01-0.96 
(d, J=5.84 Hz, 6H), 0.84 (s, 3H), 0.1 (s, 18H) Figure 33. 
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(+)-Pinanediol (1R)-(1-hexamethyldisilazaneamino-1-ethyl)-1-boronate (4d): 
20 mL of freshly distilled THF over sodium/benzophenone was placed in a round 
bottom flask and cooled to -78 oC using nitrogen/isopropanol bath. 1,1,1,3,3,3-
hexamethyl disilazane (15.9 mmol, 3.35 mL) was slowly added along the cold walls 
of the reaction vessel using a canula, then 2.5 M butyl lithium (14.5 mmol, 5.8 mL) 
was added. The reaction mixture was warmed to room temperature for 10 min, then 
cooled to – 78 oC. (-)-Pinanediol (1R)-(1-chloroethyl)-1-boronate (3d) (13.2 mmol, 
3.6 g) was added to the reaction mixture and warmed to room temperature and kept 
the reaction vessel in desiccator for 4 days. THF was distilled off at aspirator 
vacuum and the product is collected at 120 – 124 oC by distillation at 50 µm of Hg. 
The yield was 2.2 g (45%) of product as a yellow color oil. 1H NMR (400 MHz, 
CDCl3): δ 4.32-4.28 (dd, J=1.75 Hz, 1H), 2.76-2.68 (Q, J=8.06 Hz, 1H), 2.36-2.28 
(m, 1H), 2.24-2.16 (m, 1H), 2.06-2.01 (T, J=5.68 Hz, 1H), 1.92-1.87 (m, 1H), 1.87-
1.8 (m, 1H), 1.38 (s, 3H), 1.28 (s, 3H), 1.19-1.16 (d, J=7.91 Hz, 3H), 0.84 (s, 3H), 0.1 
(s, 18H) Figure 34. 
(-)-Pinanediol (1S)-(1-aminoethyl)-1-boronate (D-boroAla-(-)-pinanediol HCl 
salt) (5a) : (-)-Pinanediol (1S)-(1-hexamethyldisilazaneaminoethyl)-1-boronate (4a) 
(0.27 mmol, 100 mg) was placed in a round bottom flask and cooled to – 10 oC using 
an ice/NaCl bath, 1M HCl/ether (2 mmol, 2 mL) was added drop wise and stirred for 
1 hr. The solvent was removed using nitrogen flush and then by high vacuum 
system. The yield was 68 mg (97%) of product as a light yellow solid [88]. 1H NMR 
(400 MHz, CDCl3): δ 4.32-4.28 (dd, J=1.75 Hz, 1H), 2.92-2.88 (m, 1H), 2.76-2.68 (Q, 
J=8.06 Hz, 1H), 2.36-2.28 (m, 1H), 2.24-2.16 (m, 1H), 2.06-2.01 (T, J=5.68 Hz, 1H), 
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1.92-1.87 (m, 1H), 1.87-1.8 (m, 1H), 1.38 (s, 3H), 1.28 (s, 3H), 1.19-1.16 (d, J=7.91 
Hz, 3H), 0.84 (s, 3H) Figure 35.  
 (-)-Pinanediol (1S))-1-amino-1-propyl -1-boronate (D-boroVal-(-)-pinanediol 
HCl salt) (5b): (-)-Pinanediol (1S)-(1-hexamethyldisilazaneamino-1-propyl)-1-
boronate (4b) (0.27 mmol, 100 mg) was placed in a round bottom flask and cooled 
to – 10 oC using an ice/NaCl bath, and 1M HCl/ether (2 mmol, 2 mL) was added 
drop wise and stirred for 1 hr. The solvent was removed using nitrogen flush and 
then by high vacuum system. The yield was 69 mg (93%) of product as a light yellow 
solid [102]. 1H NMR (400 MHz, CDCl3): δ 4.32-4.28 (dd, J=1.75 Hz, 1H), 2.76-2.68 
(dT, J=6.08 Hz, 1H), 2.36-2.28 (m, 1H), 2.24-2.16 (m, 1H), 2.06-2.01 (T, J=5.68 Hz, 
1H), 1.92-1.87 (m, 1H), 1.87-1.8 (m, 1H), 1.79-1.68 (dT, J=7.36 Hz, 2H),  1.38 (s, 
3H), 1.28 (s, 3H), 1.19-1.16 (d, J=7.91 Hz, 3H) Figure 36. 
(-)-Pinanediol (1S))-1-amino-1-isobutyl-1-boronate HCl salt (5c): (-)-
Pinanediol (1S)-(1-hexamethyldisilazaneamino-1-isobutyl)-1-boronate (4c) (0.27 
mmol, 100 mg) was palced in a round bottom flask and cooled to – 10 oC using an 
ice/NaCl bath, 1M HCl/ether (2 mmol, 2 mL) was added drop wise and stirred for 1 
Hr. The solvent was removed using nitrogen flush and then by high vacuum system. 
The yield was 72 mg (93%) of product as a yellow color solid [75]. 1H NMR (400 
MHz, CDCl3): δ 4.32-4.28 (dd, J=1.75 Hz, 1H), 2.76-2.68 (dT, J=5.84 Hz, 1H), 2.36-
2.28 (m, 1H), 2.24-2.16 (m, 1H), 2.06-2.01 (T, J=5.68 Hz, 1H), 1.92-1.87 (m, 1H), 
1.87-1.8 (m, 1H), 1.38 (s, 3H), 1.28 (s, 3H), 1.19-1.16 (d, J=7.91 Hz, 3H), 1.01-0.96 
(d, J=5.84 Hz, 6H), 0.84 (s, 3H) Figure 37. 
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(+)-Pinanediol (1R)-(1-aminoethyl)-1-boronate (L-boroAla-(+)-pinanediol HCl 
salt) (5d) : (-)-(+)-Pinanediol (1R)-(1-hexamethyldisilazaneamino-1-ethyl)-1-boronate 
(4d) (0.27 mmol, 100 mg) was placed in a round bottom flask and cooled to – 10 oC 
using an ice/NaCl bath, 1M HCl/ether (2 mmol, 2 mL) was added drop wise and 
stirred for 1 Hr. The solvent was removed using nitrogen flush and then by high 
vacuum system. The yield was 68 mg (97%) of product as a yellow solid. 1H NMR 
(400 MHz, CDCl3): δ 4.32-4.28 (dd, J=1.75 Hz, 1H), 2.92-2.88 (m, 1H), 2.76-2.68 (Q, 
J=8.06 Hz, 1H), 2.36-2.28 (m, 1H), 2.24-2.16 (m, 1H), 2.06-2.01 (T, J=5.68 Hz, 1H), 
1.92-1.87 (m, 1H), 1.87-1.8 (m, 1H), 1.38 (s, 3H), 1.28 (s, 3H), 1.19-1.16 (d, J=7.91 
Hz, 3H), 0.84 (s, 3H) Figure 38. 
(1S)-(1-aminoethyl)-1-boronate (D-boroAla) (6a): D-boroala(-)Pd (5a) (0.39 
mmol, 88 mg) was dissolved in 2 mL of 1:1 ether/water solution and phenylboronic 
acid (0.78 mmol, 96 mg) was added followed by 1M HCl (0.08 mmol, 78 µL) and 
stirred for 1 Hr. The reaction mixture was extracted 2 times with ether to remove 
phenyl boronic acid and pinanediol. The product is obtained by lyophilizing the water 
layer. The yield was 32 mg (92%) of product as a yellow color solid. 1H NMR (400 
MHz, CDCl3): δ 3.46-3.39 (Q, J=6.31 Hz, 1H), 2.85-2.77 (Q, J=6.31 Hz, 1H), 2.7-
2.62 (Q, J=6.31 Hz, 1H), 1.13-1.09 (d, J=7.78 Hz, 3H), 1.06-1.01 (T, J=7.48 Hz, 1H), 
0.97-0.92 (T, J=6.73 Hz, 1H) Figure 39. 
(1R)-(1-aminoethyl)-1-boronate (L-boroAla) (6d): D-boroala(+)Pd (5d) (0.39 
mmol, 88 mg) was dissolved in 2 mL of 1:1 ether/water solution and phenylboronic 
acid (0.78 mmol, 96 mg) was added followed by 1M HCl (0.08 mmol, 78 µL) and 
stirred for 1 Hr. The reaction mixture was extracted 2 times with ether to remove 
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phenyl boronic acid and pinanediol. The product is obtained by lyophilizing the water 
layer. The yield was 31 mg (89%) of product as a yellow color solid. 1H NMR (400 
MHz, CDCl3): δ 3.46-3.39 (Q, J=6.31 Hz, 1H), 2.85-2.77 (Q, J=6.31 Hz, 1H), 2.7-
2.62 (Q, J=6.31 Hz, 1H), 1.13-1.09 (d, J=7.78 Hz, 3H), 1.06-1.01 (T, J=7.48 Hz, 1H), 
0.97-0.92 (T, J=6.73 Hz, 1H) Figure 40. 
Pinacol aminomethylboronate hydrochloride (boroGly-pinacol): The synthesis 
strategy used for boroGly-pinacol is outlined in Figure 13. 
Pinacol-1-(chloromethyl)-1-boronate (7): Diisopropyl (chloromethyl)boronate 
was synthesized following the procedure of Sadhu and Matteson, and converted in 
situ to the pinacol ester [89]. Briefly, 19.2 mL (48 mmol) of 2.5 M nBuLi in hexanes 
was added dropwise down the cold reaction vessel wall to a stirred mixture of 3.8 
mL of ClCH2I (52 mmol) and 12 mL (51 mmol) B(OiPr)3 in 60 mL of dry THF at -78 
oC under argon. After 1 h the reaction mixture was allowed to warm to 10 oC and 
stirred for an additional 30 min. The diisopropyl (chloromethyl)boronate was 
converted to the pinacol ester  in situ by first titrating the reaction mixture containing 
diisopropyl (chloromethyl)boronate with HCl/ether to the methyl orange endpoint, 
and then adding 6.03 g (51 mmol) of pinacol. The mixture was stirred overnight 
under argon, and the product isolated by distillation, first by removing volatile 
components (THF, iPrOH) by distillation at atmospheric pressure, and then rapid 
fractional distillation through a short Vigreux column under vacuum, where the 
product distilled over at 85-100 oC at 5 mm Hg to provide 8.98 g (48% overall) of the 
pure product as a clear oil. 1H NMR for (7) was as described previously.  
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Pinacol bis-(trimethylsilyl)aminomethylboronate (pinacol N,N-bis-
(trimethysilyl)-boroGlycine) (8): This reaction was performed following the general 
procedure of Matteson and Sadhu. Briefly 20 mL of freshly distilled THF over 
sodium/benzophenone was taken in a round bottom flask and cooled to -78 oC using 
nitrogen/isopropanol bath. 1,1,1,3,3,3-hexamethyl disilazane (61 mmol, 2.44 mL) 
was added to the reaction vessel, then 2.5 M butyl lithium (61 mmol, 3.5 mL) was 
added along the cold walls. The reaction mixture was warmed to room temperature 
for 10 min, then cooled to – 78 oC. Pinacol-1-(chloromethyl)-1-boronate (7) (50.9 
mmol, 8.98 g) was added to the reaction mixture and allowed to warm to room 
temperature and the reaction vessel kept in desiccator for 4 days. THF was distilled 
off at aspirator vacuum and the product is collected at 90 – 95 oC by distillation at 50 
µm of Hg. The yield was 2.25 g of product as a yellow oil. 
BoroGly-pinacol. (9): To a solution of 2.25 g of Pinacol bis-
(trimethylsilyl)aminomethylboronate (8) (7.14 mmol) in 10 mL of ether at -80 oC was 
added 11 mL (22 mmol) of a 2 M solution of hydrogen chloride in ether. The reaction 
mixture was allowed to warm to room temperature and diluted with 25 mL of hexane. 
The precipitate formed upon hexane addition was filtered, washed with hexane, and 
dried to give 1.46 g (7.07 mmol, 99%) of a white crystalline solid. 1H NMR: ä 1.279 
(s, 12H, pinacolyl), 1.506 (d, J ) 7.5 Hz, 3H, CH3CHB), 2.92-3.10 (br s, 1H, 
CH3CHB), 8.10-8.35 (br s, 3H, NH3+) [103].  
Acetyl-D-boroAla-(-)-pinanediol (10): Acetyl-D-boroAla-(-)-pinanediol was 
synthesized from D-boroAla-(-)-pinanediol as described previously [88]. D-boroAla-(-
)-pinanediol hydrochloride (5a) (0.15 mmol, 40 mg) was dissolved in 3 mL of DCM at 
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–10 oC. To this TEA (0.45 mmol, 63 µL) was added followed by acetyl chloride (0.23 
mmol, 17 µL). After 1 hr the reaction mixture was diluted with 7 mL of DCM and 
quenched with 3 mL of 1M hydrochloric acid, back extracted with 3 mL of water, 3 
mL of saturated sodium bicarbonate solution, and 3 mL of water. The organic layer 
was dried over anhydrous magnesium sulfate and evaporated to dryness to give the 
product as a white solid. Yield 38 mg. 
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Figure 10. Synthetic scheme for the synthesis of D-boro amino acid analogs  
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Figure 11. Synthetic scheme for L-boroAla-(+)Pd 
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Figure 12. Synthetic scheme for D-boroAla (6a). 
 
  
Figure 13. Synthetic scheme for boroGly pinacol (9). 
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Figure 14. Synthetic scheme for Acetyl-D-boroAla-(-)-pinanediol (10) 
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 Antibacterial Properties Characterization 
Spectrum of activity: MICs were determined against several bacterial 
pathogens (Table 3), including both Gram-positive and Gram-negative organisms. 
Minimal inhibitory concentrations (MICs): MICs were determined by broth 
microdilution generally following CLSI guidelines (Clinical and Laboratory Standards 
Institute, formerly National Committee for Clinical Laboratory Standards) [104]. Two-
fold serial dilutions of test agents were prepared in 100 µL of Mueller Hinton Broth 
(Difco) in the wells of microtiter plates. Wells were inoculated with ~1x104 cfu of the 
test bacteria, and plates incubated for 16-20 hrs at 35 oC. The plates were read for 
turbidity either visually or at 600 nm in a Tecan SpectroFluor Plus microtiter plate 
reader. The MIC was read as the lowest concentration of test compound for which 
no turbidity is apparent (Transmittance >90% of a media control well). Each 
determination was performed in triplicate. 
Minimal bactericidal concentrations (MBCs): MBCs were performed by plating 
serially diluted inhibited samples from the MIC determination onto agar media. After 
overnight (24 hrs) incubation at 35 oC, colonies were counted and used to calculate 
cfu’s of the samples. The MBC was defined as the lowest concentration of drug 
which killed 99.9% (log3 reduction) of the original inoculum. 
Frequency of resistance against D-boroAla: A clinical isolate of methicillin-
sensitive S. aureus (MSSA) was grown for 16 hours at 35 oC in 100 mL Mueller 
Hinton Broth, with shaking at 250 rpm. Bacterial cells were concentrated from 50 mL 
of this saturated overnight culture by centrifugation at 3000 rpm for 15 minutes and 
reconstituted into a volume of 5 mL media. Volumes of 0.4 mL (~1x109 cfu) were 
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plated onto 150-mm agar plates containing 75 mL of media with D-boroAla-(-)-
pinanediol at concentrations of 2x and 4x MIC. As a reference, the cfu of the 
reconstituted culture was also determined. At each concentration, 3-4 plates were 
used. Inoculated plates were incubated for 48 hours at 35 oC and each plate visually 
screened for growth of single colonies. Representative subsets of observed colonies 
were selected using a sterile inoculating loop and restreaked onto fresh media 
containing compound (at selection concentration). Colonies that did not grow on 
fresh media containing test D-boroAla against were not considered resistant. The 
frequency of resistance was calculated by dividing the number of resistant colonies 
by the total number of cfu's plated. 
Determination of in vivo L-Ala, D-Ala, and D-Ala-D-Ala levels in response to D-
boroAla-(-)-pinanediol (5a): Levels of L-Ala, D-Ala, and D-Ala-D-Ala were determined 
as described in detail previously [105]. Bacteria (Escherichia coli K12 or MRSA 
(clinical isolate)) were grown to an OD at 600 nm of 0.6 in either minimal media (E. 
coli) or Mueller Hinton broth (MRSA). To a test culture was added D-boroAla-(-)-
pinanediol (5a) to 4x MIC, and to control cultures were added no antibiotic, or one of 
two control antibiotics (tetracycline or vancomycin) at 4x their respective MICs. 
Growth inhibition was observed within 15 min. Once growth inhibition was apparent 
cultures were rapidly cooled in an ice/water bath, 4 samples of 10 mL were moved 
from each flask to ice-cold 15-ml centrifuge tubes, and the cells were pelleted by 
centrifuge at 3000 rpm for 10 min at 2 °C. Cell pellets (~50 μL) were resuspended in 
100 μL of ice-cold M9 minimal medium and treated with 200 μL of ice-cold 80% 
acetone spiked with 20 μM 13C3-D-Ala as an internal standard. Tubes were kept on 
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ice with occasional vortexing for 5 min. These tubes were again centrifuged, and 
supernatants were collected into fresh ice-cold microcentrifuge tubes. Samples (15 
µl) were derivatized with Marfey’s reagent, and analyzed by LC-MS/MS. 
Marfey’s derivatization reactions: Marfey’s derivatization was performed as 
described previously [105], briefly 15 µL of the culture extact was added to 15 µL of 
10 mM Marfey’s reagent (w/v in acetone) and then 5 µL of 1 M triethylamine. The 
contents were mixed by vortexing and incubated at 37 °C for 150 min. The 
derivatization reaction was quenched by adding 5 µL of 1 M HCl, and the sample 
was diluted to 200 µL using 75% H2O/25% acetonitrile + 0.1% formic acid and 
analyzed by LC-MS/MS. 
Chromatographic conditions: Chromatography was performed at a flow rate of 
300 μl/min, with 75% solvent A (100% H2O and 0.1% formic acid) and 25% solvent 
B (70% acetonitrile/30% H2O + 0.1% formic acid) for the first minute, followed by a 
linear gradient to 50% solvent A/50% solvent B in 11 min and then a gradient to 
100% solvent C (100% acetonitrile + 0.1% formic acid) in 1 min. 
Mass spectrometer conditions: An LC/MS/MS (MRM) separation and 
quantitation method was set up and used for quantitation of Marfey’s adducts of D-
Ala, L-Ala and D-Ala-D-Ala using the parameters detailed in Table 1. 
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Table 1. Summary of optimized parameters for MS/MS detection of Marfey's adducts 
 
   MS Parameters 
  DP (V) 60 
 EP (V) 6 
 CEP (V) Instrument Default 
   MS/MS Parameters 
  CE (V) 20 
 CXP (V) 4 
 CAD (Arb) 5 
 
   ESI Parameters 
  TEM (0C) 175 
 CUR (Arb) 30 
 GS1 (Arb) 40 
 GS2 (Arb) 50   
 
Abbreviations; Arb=Arbitrary instrument based setting;DP=declustering potential; 
EP=entrance potential; CEP=collision cell exit potential; CE=collision energy; 
CXP=collision cell exit potential; CAD=collisionally activated dissociation; 
TEM=temperature; CUR=curtain gas setting; GS1 and GS2, gas spray 1 and 2 
settings, respectively. 
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Results 
Structure-activity correlation: A summary of MICs against MSSA (clinical 
isolate), MRSA (clinical isolate), and E. coli K12 is given in Table 2. D-boroAla-(-)-
pinanediol (5a) has the most potent activity in this series. D-boroHomoAla-(-)-
pinanediol (5b), D-boroVal-(-)-pinanediol (5c), and boroGly-(-)-pinacol (9) were found 
to have worse (higher) MIC values than D-boroAla-(-)-pinanediol (5a). Removal of 
the pinanediol group also reduced antibacterial effectiveness, which is presumably 
due to the lipophilic pinanediol group facilitating transport across the bacterial 
membrane. Acetyl-D-boroAla-(-)-pinanediol (11) was completely inactive, indicating 
that a positively charged amino group is required for antibacterial activity. Finally, L-
boroAla-(+)-Pd (5d) [88] (the opposite enantiomer of 5a), had very weak activity. 
Filter disc assay was done on D-boroAla-(-)-pinanediol (5a), L-boroAla-(+)-Pd (5d) 
and pinanediol and was shown in Figure 15. 
 
Figure 15. Zone of inhibition of D-boroAla-(-)-Pd, L-boroAla-(-)-Pd and pure 
pinanediol. 
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Table 2. Structure/activity correlation of different analogues of D-boroAla 
      
MIC: µM  and (µg/mL) 
   
   
 
 
MSSA MRSA E. coli 
Cmpd 
 
(clinical) (clinical) (K12) 
5a 
 
50 (10) 50 (10) 100 (20) 
5b 
 
200 (50) 1000 (250) 1000 (250) 
5c 
 
5000 1250) 5000 (1250) 5000 (1250) 
5d 
 
1000 (250) ND1 400 (100) 
6a 
 
200 (25) 200 (25) 400 (50) 
9 
 
Weak Activity ND1 NA1 
10 
 
NA1 NA1 NA1 
1 ND – not determined, NA – no activity. 
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Minimal inhibitory concentrations: MICs were determined against several 
bacterial pathogens, that include Gram-positive bacteria like Enterococcus faecium 
(VRE, clinical), MRSA (clinical). MSSA (clinical), and Gram-negative bacteria like 
Salmonella typhi (clinical), Escherichia coli K12, Shigella sonnei (clinical), 
Pseudomonas aeruginosa (ATCC 27853), Burkholderia pseudomallei  (strain 
1026b), to determine spectrum of activity. MICs were determined for compounds D-
boroala(-)Pd (5a),D-boroAla (6a) and compared with commercially available 
antibiotics like D-cycloserine, vancomycine, tetracycline, ampicillin, and cefoxitin. 
The results were tabulated in Table 3. All MICs determinations were performed in 
triplicate.  
Bactericidal activity. D-boroAla-(-)-pinanediol (5a) was bactericidal against S. 
aureus and Bacillus subtilis at 1x MIC, and against E. coli and Salmonella enterica 
Serovar Typhimurium at 4x MIC. Results are tabulated in Table 4. 
Frequency of Resistance. A frequency of resistance determination was 
performed for D-boroAla-(-)-pinanediol (5a) against MSSA (clinical) at 2x and 4x MIC 
(16 and 32 µg/mL respectively). At 2x MIC a frequency of resistance of 1x10-6 was 
observed whereas at 4x MIC a frequency of resistance of 8x10-8 was observed.  
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Table 3. Spectrum of activity: MICs for D-boroAla-(-)-pinanediol, D-boroAla (no 
pinanediol), and control antibiotics. 
 
 
 
Table 4. MICs and MBCs for D-boroAla-(-)-pinanediol against several bacterial 
strains. 
    
    
MIC  MBC  
    
Strain   (µg/mL) 
Staphylococcus aureus 
(ATCC 29213)   
G+ 16 16 
Salmonella enterica                 
Serovar Typhimurium           
(ATCC 14028) 
G– 32 >128 
Bacillus subtilis                      
(ATCC 6633) 
G– 16 16 
Escherichia coli (K12) G– 32 >128 
 
50 
 
Marfey’s derivatization reactions: L-Ala, D-Ala, and D-Ala-D-Ala are small 
hydrophilic molecules that are not retained on reverse phase high-performance 
liquid chromatography (HPLC) media and are too small to give quantitatable ions by 
multiple reaction monitoring (MRM), which is the generally used method for 
quantitation in LC–MS/MS. Therefore, it is necessary to derivatize them for LC–
MS/MS analysis. Also, L-Ala and D-Ala are enantiomers with the same mass and, 
therefore, will need to be separated chromatographically for quantitation by LC–
mass spectrometry (MS)-based methods. Marfey’s reagent is a chiral analog of 
Sanger’s reagent that allows D- and L-amino acids to be separated by HPLC for 
quantitation [106-107, 109]. Marfey’s adducts formed after Marfey’s derivatization of 
L-Ala, D-Ala and D-Ala-D-Ala are shown in Figure 16. After Marfey’s derivatization of 
L-Ala and D-Ala have become diasteriomers which are easily separable on HPLC 
column. A sample MRM chromatogram for an untreated E. coli extract was shown in 
Figure 17. The top panel represents the LC–MS/MS chromatogram detected at m/z 
342.2/297.2 (Q1/Q3), which is specific for the Marfey’s derivatives of β-Ala (left peak 
at 5.6 min), L-Ala (center peak at 8.2 min, 15 pmol), and D-Ala (right peak at 9.6 min, 
10 pmol). The center panel represents analogous data at m/z 345.2/200.2, which is 
specific for the Marfey’s derivative of 13C3-D-Ala used as an internal standard 
(20 pmol), and the bottom panel represents analogous data for m/z 413.2/358.2, 
which is specific for the Marfey’s adduct of D-Ala-D-Ala (peak at 8.7 min, ∼3 pmol). 
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Figure 16. Marfey’s reagent and reactions to give adducts with L-Ala, D-Ala and D-
Ala-D-Ala. Adapted from Jamindar et. al. 2010. 
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Figure 17. Sample MRM chromatogram for an untreated E. coli extract. The top 
panel represents the LC–MS/MS chromatogram specific for the Marfey’s derivatives 
of β-Ala (peak at 5.6 min), L-Ala (peak at 8.2 min), and D-Ala (peak at 9.6 min). The 
center panel represents Marfey’s derivative of 13C3-D-Ala used as an internal 
standard and the bottom panel represents Marfey’s derivative of D-Ala-D-Ala (peak 
at 8.7 min). Adapted from Jamindar et. al. 2010. 
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Discussion 
Previous biochemical studies [99] have identified D-boroAla as an effective 
inhibitor of both alanine racemase (saturable time dependent inhibition with KI = 20 
mM and kinact = 0.35 min-1) and D-Ala-D-Ala ligase (KI under intracellular conditions 
against the S. Typhimurium enzyme of 18 µM). There have however been no 
previous reports on the antibacterial activity of D-boroAla. During the course of our 
investigations on peptide-D-boroAla derivatives as inhibitors of the penicillin-binding 
proteins [88] we observed antibacterial activity in some crude peptide-D-boroAla 
preparations which was lost on purification of the peptide-D-boroAla derivative. A 
filter disc test of D-boroAla (6a) for antibacterial activity revealed surprisingly good 
activity for D-boroAla-(-)-Pd (5a) against both E. coli and S. aureus indicating 
possible broad spectrum activity, and it seemed worthwhile to further characterize 
the antibacterial activity of D-boroAla and its homologs.  
A structure-activity study was first performed by synthesizing a series of D-
boroAla homologs. Three features of D-boroAla were examined including; 1) the 
length of the side chain alkyl group, 2) the effect of N-acylation, and 3) the effect of 
the presence or absence of the pinanediol protecting group. Pinanediol protecting 
groups are used in amino boronic acid syntheses to control the stereochemical 
outcome of the product [75, 110-111]. In aqueous solutions the boro-pinanediol ester 
is in equilibrium with the free boronic acid and pinanediol. A control test of racemic 
pinanediol revealed no antibacterial activity (data not shown). Among the 
compounds tested in this study, D-boroAla-(-)-pinanediol was the most active, with 
MICs against E. coli and S. aureus in the 8 to 32 µg/mL range Table 2 and Table 3.    
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Removal of the pinanediol group resulted in higher MICs, likely due to the 
lipophilic pinanediol group facilitating membrane permeability. L-boroAla showed 
much lower antibacterial activity, demonstrating stereospecificity of the antibacterial 
activity. This observation indicates that D-boroAla likely acts on a specific 
macromolecular target, and not simply as a non-specific membrane disrupting agent. 
Longer and shorter side chain homologs of D-boroAla (e.g. boroGly, D-boroHomoAla, 
and D-boroVal) demonstrated greatly reduced antibacterial activity. Acetylation of D-
boroAla to give acetyl-D-boroAla abolished activity, demonstrating that a positively 
charged amine group is required for antibacterial activity.  
Activity of D-boroAla was then tested against several Gram negative and 
Gram positive pathogenic bacteria to determine spectrum of activity Table 3. Broad 
spectrum activity against both Gram-positive and Gram-negative bacteria was 
observed, with MICs ranging from 8 to 128 µg/mL.  Bactericidal activity was 
apparent at 1x MIC against S. aureus and B. subtilis, and at 4x MIC against S. 
Typhimurium and E. coli Table 4.  
The frequency of resistance at 4x MIC was 8x10-8. This is comparable to or 
lower than rifampicin resistance frequency in several bacterial strains [112-113] and 
falls at the lower end of the weakly hypermutable range (4x10-8 to 4x10-7), and just 
above the normomutable range (8x10-9 to 4x10-8) [114-115]. These are generally 
favorable characteristics, except for the frequency of resistance which is somewhat 
on the high side for a prospective antibacterial agent. Given these observations, an 
obvious question was: what is the molecular target of D-boroAla? Several lines of 
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evidence suggested that D-boroAla would act in the alanine branch of the bacterial 
cell wall biosynthesis pathway Figure 9, including that bacterial cell wall 
biosynthesis is unique in its requirement for D-Alanine, that the antibacterial activity 
in this series of compounds is correspondingly specific to D-boroAlanine Table 2, 
and that D-boroAla has previously been described as an inhibitor of both alanine 
racemase and D-Ala-D-Ala ligase [99] – the two enzymes catalyzing the reactions in 
the alanine branch Figure 9. We have recently developed an assay for the 
intermediates (L-Ala, D-Ala, and D-Ala-D-Ala) in the alanine branch of bacterial cell 
wall biosynthesis [105]. This assay was used to determine whether D-boroAla had a 
significant impact on the early cell wall intermediates in both E. coli and S. aureus 
and demonstrate that D-boroAla has a substantial effect on the level of D-Ala-D-Ala 
above its MIC in both E. coli Figure 18 and S. aureus Figure 19. This effect is 
centered on the MIC for D-boroAla Figure 18 –D-boroAla exhibits little effect on D-
Ala-D-Ala levels below its MIC, but a pronounced effect above its MIC. It is also 
notable that the control antibiotic cycloserine exerts its effect on both D-Ala and D-
Ala-D-Ala levels, consistent with its known mechanism of action as an alanine 
racemase inhibitor. From these observations, we conclude that D-boroAla exerts its 
antibacterial activity through inhibition of DDL. As a further test of biochemical 
mechanism, it is known that in S. aureus that the addition of D-Ala can antagonize 
the antibacterial action of cycloserine [116-117]  which targets alanine racemace. 
We have also observed that D-Ala at 2.5 mm antagonizes the antibacterial activity of 
cycloserine at 2× and 4× MIC, but does not antagonize the antibacterial activity of D-
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boroAla at 2× and 4× MIC, which is an observation also consistent with DDL as the 
molecular target of D-boroAla. 
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Figure 18. Levels of L-Ala, D-Ala, and D-Ala-D-Ala in E. coli as a function of added 
agents. 
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Figure 19. Levels of L-Ala, D-Ala, and D-Ala-D-Ala in S. aureus as a function of no 
added D-boroAla-(-)-Pd (control) and 4x MIC of added D-boroAla-(-)-Pd. This 
experiment was performed as described for E. coli in the main text, with the 
exception that since S. aureus is fastidious it was necessary to grow in Mueller 
Hinton Broth. Because of background levels of amino acids in Mueller Hinton Broth, 
cells were washed 3x in ice cold minimal media prior to lysis and metabolite 
analysis. 
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The identification of DDL as the molecular target of D-boroAla’s antibacterial 
activity can be used to rationalize the MBC/MIC ratios observed against several 
bacterial strains Table 4. The difference in MBC/MIC ratio between bacterial strains 
appears correlated with the number of copies of DDL in the genomes of these 
organisms (1 in S. aureus and B. subtilis, and 2 in E. coli and S. Typhimurium). Our 
working hypothesis is that at 1x MIC D-boroAla inhibits the one DDL in S. aureus and 
B. subtilis, and is bactericidal. However, against E. coli and S. Typhimurium which 
have two copies of DDL, 1x MIC D-boroAla inhibits only one of the two DDLs which 
inhibits grown, while the other DDL appears capable of keeping these organisms 
viable. At higher D-boroAla concentrations (4x MIC) both DDLs in E. coli and S. 
Typhimurium are inhibited by D-boroAla, which then causes cell death.  
Conclusions and Future Directions 
This study demonstrates that D-boroAla has effective broad spectrum 
antibacterial activity, is bactericidal, and acts on D-Ala-D-Ala ligase. There has 
recently been considerable interest in D-Ala-D-Ala ligase as a potential target for 
antibacterial agent development [118], and the observations reported here further 
support D-Ala-D-Ala ligase as a viable target for the development of novel 
antibacterial agents. Future studies directed towards characterizing D-boroAla 
against the two DDL variants found in E. coli and S. Typhimurium will be of interest 
to determine which of these DDLs in of lower and higher affinity, and their correlation 
with D-boroAla’s in vivo activity. This study also raises the question of why do some 
bacteria have two copies of DDL. One explanations is that two different DDL 
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enzymes with different kinetic properties may be required to allow efficient bacterial 
cell growth or survival under different growth condition, for example under nutrient 
rich or nutrient starved conditions. D-boroAla and gene knockout experiments could 
be used to address this question.  
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Figure 20. NMR spectrum of Diisopropyl-(1-methyl)-1-borate (1a) 
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Figure 21. NMR spectrum of Diisopropyl-(1-ethyl)-1-borate (1b) 
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Figure 22. NMR spectrum of Diisopropyl-(1-isopropyl)-1-borate (1c) 
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Figure 23. NMR spectrum of (-)-Pinanediol-(1-methyl)-1-boronate (2a) 
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Figure 24. NMR spectrum of (-)-Pinanediol-(1-ethyl)-1-boronate (2b) 
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Figure 25. NMR spectrum of (-)-Pinanediol-(1-isopropyl)-1-boronate (2c) 
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Figure 26. NMR spectrum of (+)-Pinanediol-(1-methyl)-1-boronate (2d) 
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Figure 27. NMR spectrum of (-)-Pinanediol (1R)-(1-chloroethyl)-1-boronate (3a) 
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Figure 28. NMR spectrum of (-)-Pinanediol (1R)-(1-chloro-1-propyl)-1-boronate (3b) 
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Figure 29. NMR spectrum of (-)-Pinanediol (1R)-(1-chloro-1-isobutyl)-1-boronate (3c) 
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Figure 30. NMR spectrum of (+)-Pinanediol (1S)-(1-chloroethyl)-1-boronate (3d) 
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Figure 31. NMR spectrum of (-)-Pinanediol (1S)-(1-hexamethyldisilazaneaminoethyl)-1-boronate (4a)
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Figure 32. NMR spectrum of (-)-Pinanediol (1S)-(1-hexamethyldisilazaneamino-1-propyl)-1-boronate (4b) 
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Figure 33. NMR spectrum of (-)-Pinanediol (1S)-(1-hexamethyldisilazaneamino-1-isobutyl)-1-boronate (4c) 
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Figure 34. NMR spectrum of (+)-Pinanediol (1R)-(1-hexamethyldisilazaneamino-1-ethyl)-1-boronate (4d) 
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Figure 35. (-)-Pinanediol (1S)-(1-aminoethyl)-1-boronate (D-boroAla-(-)-pinanediol) (5a) 
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Figure 36. (-)-Pinanediol (1S))-1-amino-1-methylethyl-1-boronate (D-boroVal-(-)-pinanediol) (5b) 
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Figure 37. (-)-Pinanediol (1S))-1-amino-1methylisopropyl-1-boronate (5c)
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Figure 38. NMR spectrum of (+)-Pinanediol (1R)-(1-aminoethyl)-1-boronate (L-boroAla-(+)-pinanediol) (5d) 
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Figure 39. NMR spectrum of (1S)-(1-aminoethyl)-1-boronate (D-boroAla) (6a) 
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Figure 40. NMR spectrum of (1R)-(1-aminoethyl)-1-boronate (L-boroAla) (6d) 
 81 
 
CHAPTER 3 
AN LC-MS/MS ASSAY FOR D-ALA-D-LAC: A KEY INTERMEDIATE FOR 
VANCOMYCIN RESISTANCE IN VANCOMYCIN-RESISTANT ENTEROCOCCUS 
Introduction and Rationale 
Enterococcus spp. are commensal bacteria of the intestine in humans and 
animals, which can cause problematic infections of the gastrointestinal tract and soft 
tissues [119-120]. Vancomycin (Vm), a glycopeptide antibiotic, is one of the most 
important antibacterial agents for the treatment of Gram-positive bacterial infections 
resistant to most other antibacterial agents, including Vm sensitive enterococcal 
(VSE) and MRSA infections [121-123]. Vancomycin-resistance enterococci (VRE), 
first reported in late 1980s [1], are now widespread and a common cause of 
nosocomial infections [2]. Given resistance to most alternative classes of 
antibacterial agents, treatment options for VRE are limited [120, 124].  
Cell wall biosynthesis is a biochemically unique bacterial pathway, which is 
the target of a number of antibacterial agents. This pathway is complex, and has 
both highly conserved elements between bacterial species, as well as important 
differences [64, 125-132]. Vancomycin exerts its antibacterial effect by binding to the 
D-Ala-D-Ala termini of pentapeptide peptidoglycan precursors [42, 133-136], thereby 
interfering with the last steps of bacterial cell wall biosynthesis. In the most clinically 
common resistance mechanisms in VRE, the terminal D-Ala-D-Ala moiety of 
peptidoglycan precursors is replaced by D-Ala-D-Lac [42-43]. This alternative 
pathway requires 4 enzymes to synthesize D-Ala-D-Lac (VanH and VanA), and to 
degrade D-Ala-D-Ala intermediates before they can be incorporated into nascent 
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peptidoglycan (VanX and VanY) Figure 41. Alanine branch metabolites (L-Ala, D-
Ala, D-Ala-D-Ala), and D-Ala-D-Lac in particular, are key intermediates in this 
process. However, these are small hydrophilic molecules, and there has been a lack 
of analytical methods for the quantitation of in vivo levels of these metabolites. While 
methods are available for D-Ala-D-Lac quantitation using radiolabeled precursors, 
such methods are apparently limited to in vitro generated analytes [137-138]. Such 
methods are inadequate for detailed or in vivo studies of alanine branch metabolite 
changes in response to vancomycin in VRE, which are at the core of the vancomycin 
resistance mechanism.  
Marfey’s reagent is a chiral analog of Sanger’s reagent used to derivatize 
chiral amino acid mixtures prior to separation on achiral media to determine 
stereochemical purity [106-107, 139]. In recent studies, we have developed a 
Marfey’s reagent-based LC-MS/MS method to quantitate alanine branch 
intermediates – L-Ala, D-Ala, and D-Ala-D-Ala – in the standard bacterial cell wall 
biosynthesis pathway [105]. This method has been used to determine the 
mechanism of antibacterial activity of cycloserine and D-boroAlanine [140-141]. In 
thus study, this method is extended to the detection and quantitation of D-Ala-D-Lac, 
the key intermediate for most types of vancomycin resistance, and demonstrated for 
determining the effect of vancomycin induction on alanine branch metabolites – 
including D-Ala-D-Lac – in VRE.  
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Figure 41. Cell wall intermediate biosynthesis pathway in VRE. Cell wall biosynthesis intermediates and enzymes 
specific to the vancomycin resistance pathway are shown in italicized bold text. NAM=N-acetylmuramic acid.
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 84 
 
Materials and Methods 
General: Vancomycin-resistant enterococcus (VRE) was a clinical isolate 
provided by Dr. Betty Herndon (University of Missouri-Kansas City, School of 
Medicine). D-Ala, L-Ala, D-Ala-D-Ala, 13C3-D-Ala, vancomycin, trifluoroacetic acid 
(TFA), hemin, and carbonyldiimidazole (CDI) were purchased from Sigma-Aldrich 
Corp (St. Louis, MO). Boc-D-Ala-OH and D-Lac-OtBu were purchased from Bachem 
Bioscience (King of Prussia, PA). C18-silica gel was from Sep-Pak Cartridges 
(Waters, Milford MA). Marfey’s reagent (1-fluoro-2,4-dinitripheny-L-5-alanine amide) 
was purchased from Novabiochem (a division of EMD Chemicals, Gibbstown, NJ). 
Other reagents were from standard sources and were reagent grade or better. VRE 
growth media – consisting of brain heart infusion (37.5 g/L), NaCl (6.5 g/L), hemin 
(10 µg/mL), and NAD+ (10 µg/mL) - was prepared following standard procedures. 
M9 minimal media – consisting of Na2HPO4 (6 g/L), KH2PO4 (3 g/L), NH4Cl (1 g/L), 
NaCl (0.5 g/L), MgSO4·7H2O (1 mM), FeSO4·7H2O (3 μg/L), vitamin B1 (thiamine, 
0.5 mg/L), and glycerol (20%, as carbon source) – was also prepared following 
standard procedures. LC-MS/MS was performed using electrospray ionization (ESI) 
in positive mode on an AB-Sciex 2000 QTrap LC-MS/MS mass spectrometer 
(Framingham, MA) equipped with an Agilent 1100 HPLC system (Santa Clara, CA). 
Data acquisition and processing were performed using the Analyst 1.4.2 software 
package (Applied Biosystems, Foster City CA). All chromatographic separations 
were performed on a Nucleodur 100-3 C8 125 x 2.0 mm column (Macherey–Nagel, 
Bethlehem PA). All centrifuge operations were performed on Sorvall RT6000 
refrigerated Centrifuge.  
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Boc-D-Ala-D-Lac-OtBu: Boc-D-Ala-OH (1.1 eq, 3.8 mmol, 710 mg) was 
dissolved in anhydrous THF (10 mL), cooled to 0 oC, and carbonyldiimidazole (1.1 
eq, 3.8 mmol, 610 mg) added. The reaction was allowed to proceed for 30 min to 
form the acyl imidazole intermediate. D-Lac-OtBu (1 eq, 3.4 mmol, 500 mg) was 
then added, and the mixture allowed to warm to room temperature. After 2 days, the 
reaction was quenched with 2M acetic acid (10 mL) and extracted three times with 
methylene chloride (3x15 mL), and the combined organic extracts back extracted 
with 1M HCl (1x5 mL), 1M NaHCO3 (1x5 mL) and brine (1x5 mL). The organic 
extract was dried over anhydrous MgSO4, filtered, and solvent removed by rotary 
evaporation. The product was obtained as a light clear oil. Yield 76%. LC-MS; 
expected [M+H ]+ = 318.18 observed [M+H ]+ = 318.20. 
D-Ala-D-Lac: Boc-D-Ala-D-Lac-OtBu (1.6 mmol, 500 mg) was placed in a 
round bottom flask and treated with TFA (5 mL) for 1 hr. TFA was removed by 
evaporation using nitrogen gas stream, and then under vacuum (5 µmHg) for 2 hrs. 
The product was a clear oil, which was dissolved in water to yield a concentrated 
stock solution of D-Ala-D-Lac. LC-MS; expected [M+H ]+ = 161.97 observed [M+H ]+ 
= 162.10. 
Preparation of standard solutions and quality control (QC) samples: 10 mM 
stock solutions of each analyte (D-Ala, L-Ala, D-Ala-D-Ala, and D-Ala-D-Lac) were 
prepared in water. An equimolar “standard mixture” was prepared by mixing aliquots 
of 60 µL of 10 mM stock solutions of L-Ala, D-Ala, D-Ala-D-Ala, and D-Ala-D-Lac with 
760 μL of H2O to give 1 mL of 0.6 mM of each. For method validation, QC samples 
of three concentrations of a mixture of all the analytes (400, 40 and 1 pmol) were 
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prepared in VRE extract. 20 µM 13C3-D-Ala was added to all samples as an internal 
standard. All solutions were stored at -20o C until use. 
Marfey’s Derivatization Reactions: To a 15 μL aliquot of the standard mixture 
was added 15 μL of 10 mM of Marfey’s reagent (in acetone) and then 5 μL of 1 M 
triethylamine (in water). The contents were mixed well and kept in an incubator at 37 
oC for 150 minutes. The derivatization reaction was quenched and acidified by 
addition of 5 μL 1 M HCl, and the sample diluted up to 200 μL with 75% H2O/25% 
acetonitrile + 0.1 % formic acid. This Marfey’s derivatized “standard mixture” was 
used in initial experiments to optimize separation and quantitation parameters. 
Individual Marfey’s adducts of L-Ala, D-Ala, D-Ala-D-Ala, and D-Ala-D-Lac were 
similarly prepared from 15 µL aliquots of 0.6 mM stocks following the same 
derivatization procedure. 
MS and MS/MS optimization: Salts were observed to interfere with MS 
detection of Marfey’s derivatives. To remove salts prior to MS and MS/MS 
optimization, a 50 μL sample of the Marfey’s derivatized standard mixture of 
individual compound was loaded onto 100 mg of C18-silica in a 1 mL syringe 
prepared by first washing with MeOH (1 mL) and then pre-equilibrated with 1 mL of 
H2O + 0.1% formic acid. After loading, the resin was washed with 100% H2O + 0.1% 
formic acid and then 20% AcCN/ H2O + 0.1% formic acid. Marfey’s adducts were 
then eluted with 75% AcCN/25% H2O + 0.1% formic acid to provide a sample of 
Marfey’s adducts free of salts. MS, MS/MS and flow (LC-MS/MS) parameter 
optimization were performed using desalted Marfey’s adduct samples using the 
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automated quantitative optimization routines in Analyst. Optimized detection and 
quantitation values were given in Table 5 
Chromatographic conditions: Chromatography was performed at a flow rate of 
300 μL/min, with 75% solvent A (100% water and 0.1% formic acid) and 25% solvent 
B (70% acetonitrile/30% water + 0.1% formic acid) for the first minute, followed by a 
linear gradient to 50% solvent A/50% solvent B in 11 min, then a gradient to 100% 
solvent C (100% acetonitrile + 0.1% formic acid) in 1 min.  
Bacterial Growth and Vancomycin Treatment: A saturated overnight culture of 
VRE was grown in an incubator-shaker at 35 oC in VRE media. Cells were harvested 
by centrifugation, and resuspended to the desired optical density (0.05 O.D at 600 
nm) in fresh VRE media. 75 mL of this culture was placed into sterilized 250 mL 
baffled shaker flasks. Vancomycin was added to flasks at different concentrations (0, 
0.032, 0.125, 1, 8, 32, and 128 µg/mL) and the flasks were incubated with good 
agitation at 35 oC. Cell growth was monitored by absorbance at 600 nm. When the 
cultures reached 0.6 OD they were rapidly cooled in an ice-water bath, 4 samples of 
10 mL each were removed from each flask to ice-cold 15 mL centrifuge tubes, and 
the cells pelleted by centrifuge at 3000 rpm for 10 min at 2 oC.  
Cell Washing and Extraction: A sample of Marfey’s derivatized VRE media 
was analyzed by LC-MS/MS and found to contain significant levels of L-Ala. To 
remove exogenous L-Ala from the bacterial cells, which would interfere with 
determination of endogenous L-Ala, we incorporated a step where VRE cells were 
washed with minimal media prior to metabolite extraction. Cell pellets (~50 μL) were 
washed by resuspending in 300 µL of ice-cold M9 minimal media, and the cells were 
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re-pelleted and wash media removed. To validate and monitor washing, 100 µM of 
γ-aminobutyric acid (GABA) was added as a marker to the VRE culture sample on 
ice prior to pelleting. After extraction as described below and derivatization with 
Marfey’s reagent, the Marfey’s adduct of GABA was quantitated. GABA analysis 
from cells washed one to four times was performed. Metabolites were extracted from 
VRE cell pellets by resuspending in 100 μL of ice-cold M9 minimal media, followed 
by addition of 200 μL ice-cold 80% acetone/water spiked with 20 μM of 13C3-D-Ala 
as internal standard. Tubes were kept on ice with occasional vortexing for 5-10 min. 
These tubes were again centrifuged to pellet cell debris and supernatants removed 
to fresh ice-cold microcentrifuge tubes. Samples (15 μL) were taken and subjected 
to Marfey’s derivatization as described above. 
Method Validation: Validation was done for selectivity, linearity, lower limit of 
quantification (LLOQ), limit of detection (LOD), accuracy, precision, recovery and 
stability as per recommendations for bioanalytical method validation by the Food and 
Drug Administration [142]. For linearity and LLOQ determination, serial dilutions of a 
1:1:1:1 mixture of L-Ala:D-Ala:D-Ala-D-Ala:D-Ala-D-Lac in steps of two were 
prepared in water with 20 µM 13C3-D-Ala internal standard included. For LOD 
determination and to check for matrix (VRE extract) effect, an identical serial dilution 
was prepared in VRE culture extract. These serially diluted samples were 
derivatized with Marfey’s reagent as described above, and LC-MS/MS analysis was 
performed on 10 μL injections. Calibration curves were constructed by plotting LC-
MS/MS peak areas of the analyte (values from blank samples of VRE extract were 
subtracted from VRE extract values to correct for the endogenous concentration of 
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each analyte) versus the concentration of each analyte by linear regression. The 
LLOQ was defined as the concentration which gave a signal/noise ratio of 10. The 
LOD was defined as the concentration that gave a signal/noise ratio of 3. For inter- 
and intraday precision and accuracy determination, QC samples were used at low, 
mid, and high analyte levels (1, 40 and 400 pmol respectively, n=6). Analyte stability 
was performed on QC samples (1, 40 and 400 pmol, n=3). Freeze/thaw stability was 
determined after three freeze/thaw cycles. For long-term (pre-derivatization) stability 
determination – QC samples were stored at -20 0C for 90 days, and for post-
derivatization stability determination – derivatized QC samples were kept at 
autosampler conditions (room temperature) for 48 hrs. 
Results and Discussion 
Washing method: Since VRE media was found to contain a significant level of 
L-Ala, a washing step with minimal media was necessary to remove exogenous L-
Ala from VRE cells before extraction. GABA added to the cells immediately after 
cooling and prior to collection was used as a marker to assess washing efficiency. 
To determine the number of washing steps required, samples after one to four 
washings were prepared and analyzed for GABA using Marfey’s derivatization and 
LC-MS/MS detection. After the third washing, the residual GABA level was 
undetectable Figure 42, and three washings were therefore used in all subsequent 
experiments.  
LC-MS/MS method development: Marfey’s derivatives of L-Ala, D-Ala, D-Ala-
D-Ala, and D-Ala-D-Lac were prepared, and found to be well separated Figure 43. 
The standard Analyst quantitative optimization algorithms were run to optimize for 
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LC–MS/MS based quantitation of a desalted sample of Mar-D-Ala-D-Lac. 
Fragmentation of the precursor ion revealed that the most intense product ion peak 
for Mar-D-Ala-D-Lac was the result of a neutral loss of 45 Da ([M+H-45]+, analogous 
to the pattern observed for Mar-L-Ala, Mar-D-Ala, and Mar-D-Ala-D-Ala [140]. This -
45 Da product ion peak was selected for use in MRM detection and quantitation of 
Mar-D-Ala-D-Lac. The key parameters for Mar-D-Ala-D-Lac were the same as for the 
Mar-D-Ala-D-Ala [140].  
Linearity and matrix effect: Linearity was confirmed by analysis of seven-point 
calibration curves for all four analytes (D-Ala, L-Ala, D-Ala-D-Ala, and D-Ala-D-Lac) 
over the range of 0-500 pmol Figure 44. All four analytes were included to ensure 
linearity and lack of matrix effects in VRE extract. Since these metabolites are 
endogenous, the calibration curve for serial dilutions in VRE extract was plotted after 
subtracting the blank values. This calibration range was found to be suitable for the 
determination of these analytes in VRE extracts, and sensitivity and linearity factors 
in both water and VRE extract are summarized in Table 6. All four analytes showed 
good linearity in this range with R2>0.99, and without appreciable matrix effects. 
LLOQ and LOD for all four analytes were 1.2 pmol and 0.6 pmol respectively.  
Accuracy, precision, and recovery: The only extraction step in this 
experimental protocol is the acetone extraction step, which is the earliest possible 
point for the addition of an internal standard. Amino acids and dipeptides (L-Ala, D-
Ala, D-Ala-D-Ala and D-Ala-D-Lac) are highly soluble in acetone-water mixtures – 
with 100% recoveries expected in the cell extraction step, and a second extraction of 
the cell pellet revealed no detectible levels of these analytes – consistent with 100% 
 91 
 
recoveries. In general, high-percentage recoveries are not a critical factor for a 
bioanalytical assay; reproducibility is the important factor [143]. The highly 
reproducible signals from the 13C3-D-Ala internal standard and analytes Figure 45 
demonstrate the reproducibility of this method. The intrarun and the interrun 
precisions were between 4 and 6%, and the intrarun and the interrun accuracies 
were between 3 and 5%.  
Stability: In our previous study of Marfey’s derivatization-based analysis of L-
Ala, D-Ala and D-Ala-D-Ala, samples kept cold on ice before derivatization with 
Marfey’s reagent were stable for at least 2 hrs, however, samples warmed to more 
than 10 oC demonstrated some conversion of 13C3-D-Ala to 13C3-L-Ala [140]. 
Similarly, samples containing underivatized D-Ala-D-Lac were stable for at least 2 
hrs when stored on ice, and for at least 90 days when stored frozen at -20 oC. 
Derivatized samples containing Mar-D-Ala-D-Lac were stable for at least 48 hrs at 
room temperature, three cycles of freeze-thaw, and 3 months at -20 oC (changes of 
less than 4%).  
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Table 5. Summary of optimized parameters for MS/MS detection of Marfey's adducts 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Abbreviations; Arb=Arbitrary instrument based setting;DP=declustering potential; 
EP=entrance potential; CEP=collision cell exit potential; CE=collision energy; 
CXP=collision cell exit potential; CAD=collisionally activated dissociation; 
TEM=temperature; CUR=curtain gas setting; GS1 and GS2, gas spray 1 and 2 
settings, respectively. 
 
 
 
 
 
   
MS Parameters 
  
DP (V) 60 
 
EP (V) 6 
 
CEP (V) Instrument Default 
   
MS/MS Parameters 
  
CE (V) 20 
 
CXP (V) 4 
 
CAD (Arb) 5 
 
   
ESI Parameters 
  
TEM (0C) 175 
 
CUR (Arb) 30 
 
GS1 (Arb) 40 
 
GS2 (Arb) 50   
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Figure 42. Measured levels of γ-aminobutyric acid (GABA) during washing. Error 
bars represent the standard error (n = 4) for each measurement. 
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Figure 43. Representative LC–MS/MS chromatograms of Marfey’s derivatized 
metabolites extracted from VRE. Peak identities were verified using standards. Top 
panel: LC–MS/MS chromatogram detected at m/z 342.2/297.2 (Q1/Q3), which is 
specific for the Marfey’s adduct of L-Ala (12.4 min) and D-Ala (13.8 min). Middle 
panel: Analogous data for m/z 413.2/368.2, which is specific for the Marfey’s adduct 
of D-Ala-D-Ala (12.5 min). Bottom panel: Analogous data for m/z 414.2/369.2, which 
is specific for the Marfey’s adduct of D-Ala-D-Lac (peak at 16.2 min). A peak for the 
+1 isotopomer of D-Ala-D-Ala is also seen (12.5 min), but this peak is well resolved 
chromatographically from D-Ala-D-Lac (16.2 min) and does not interfere with 
quantitation of D-Ala-D-Lac. 
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Figure 44. Standard curves for L-Ala, D-Ala, D-Ala-D-Ala, and D-Ala-D-Lac serially diluted in water (left panel) and VRE 
extract (right panel), derivatized with Marfey’s reagent, and quantitated using the developed LC–MS/MS method. 
Because VRE has background levels of these metabolites, blank values were subtracted before plotting the values in 
the right panel. Each point represents the average of four determinations. Diamonds (♦), Mar-D-Ala; squares (■), Mar-
L-Ala; triangles (▴), Mar-D-Ala-D-Ala; circles (●), Mar-D-Ala-D-Lac. 
 
  
 9
6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45. Measured levels of 13C3-D-Ala (internal standard), L-Ala, D-Ala, D-Ala-D-Ala, and D-Ala-D-Lac from extracts of 
VRE grown at different levels of vancomycin. Each data point is from the extract of 7.0 μg dry cells. 
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Figure 46. Data for D-Ala, D-Ala-D-Ala, and D-Ala-D-Lac in Figure 45 normalized to corresponding levels of L-Ala in 
Figure 45. 
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Table 6. Analyte sensitivity and linearity characteristics in water and VRE extract (matrix). 
 
Analytes Slopes(AU/pmol) ± SE R2 
Linear 
range 
(pmol) 
LLOQ 
(pmol) 
LOD (pmol) 
  Water VRE Water VRE 
   
Mar-D-Ala 185  ± 3 199  ± 4 0.999 0.998 
400 - 1 1.17 0.59 
Mar-L-Ala 79    ± 3 88    ± 3 0.994 0.996 
Mar-D-Ala-D-Ala 103  ± 2 111  ± 4 0.994 0.992 
Mar-D-Ala-D-Lac 38.3 ± 1.0 42.5 ± 0.6 0.999 0.997 
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Selectivity: The selectivity of a Marfey’s derivatization approach for the LC-
MS/MS quantitation of L-Ala, D-Ala, and D-Ala-D-Ala has been demonstrated 
previously [140]. D-Ala-D-Lac is one mass unit higher in molecular mass than D-Ala-
D-Ala. The +1 Da isotopomer of D-Ala-D-Ala will therefore have the same nominal 
molecular mass as D-Ala-D-Lac, which could pose a selectivity problem if these two 
analytes are not well separated chromatographically since the +1 Da isotopomer of 
D-Ala-D-Ala would also show up in the D-Ala-D-Lac MS/MS channel. A UV-vis 
monitored chromatogram demonstrated that Mar-D-Ala-D-Lac was well separated 
from Mar-D-Ala-D-Ala using our standard chromatographic conditions. After MRM 
optimization, Mar-D-Ala-D-Ala was only apparent in the D-Ala-D-Ala channel (Figure 
43, middle panel), as expected. A +1 Da isotopomer signal was also observed in the 
D-Ala-D-Lac channel, also as expected (Figure 43, bottom panel), but 
chromatographic separation was very good and provided for analyte selectivity. D-
Ala-D-Ala and D-Ala-D-Lac can therefore be quantitated independently using the 
Marfey’s derivative-based method developed here. Further evidence of selectivity is 
that D-Ala-D-Lac was undetectable in vancomycin sensitive bacteria such as 
Escherichia coli and Staphylococcus aureus (data not shown). 
Application of this method to quantitation of D-Ala-D-Ala and D-Ala-D-Lac in 
VRE: This method was then demonstrated for the quantitation of these key 
metabolites in VRE. Measured levels of the internal standard (13C3-D-Ala) were 
highly reproducible Figure 45, demonstrating low experimental error in the 
extraction, derivatization, and LC–MS/MS steps. The variations observed in the raw 
L-Ala and D-Ala levels were strongly correlated (Figure 45, correlation 
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coefficient = 0.99), with only a weak correlation with vancomycin concentration 
(correlation coefficient = −0.60), indicating that variation in these metabolites was 
due to differences in cultures before the addition of the internal standard (13C3-D-Ala) 
and with only weak dependence on vancomycin concentration. The observed 
variation was also uncorrelated with the cell density (OD at 600 nm) at the time of 
harvesting (data not shown). Normalization of the D-Ala, D-Ala-D-Ala, and D-Ala-D-
Lac levels using their L-Ala levels, with the L-Ala level at 0 μg/ml vancomycin 
(70.7 pmol/μg dry cells) as the reference value, was performed (Eq. (1)): 
equation(1) 
 
where [X]i (normalized) = normalized concentration of the X metabolite in the ith 
sample; [X]i (un-normalized) = un-normalized concentration of the X metabolite in 
the ith sample; [LA]0 = concentration of L-Ala in the control ([vancomycin] = 0) 
sample (70.7 pmol/μg dry cells); and [LA]I = concentration of L-Ala in the ith sample. 
This normalization approach shows substantially reduced variation for the d-Ala data 
[σ2d-Ala in Figure 45 = 34 (pmol/μg dry cells)2 and σ2D-Ala in Figure 46 = 3.1 (pmol/μg 
dry cells)2]. The use of a core metabolite such as L-Ala as a reference, therefore, 
substantially corrects for variation between different culture flasks. 
Exposure to vancomycin results in a concentration-dependent lowering of the 
D-Ala-D-Ala level Figure 45, with a midpoint around 0.06 μg/ml vancomycin. This 
decrease in D-Ala-D-Ala level is consistent with induction of the VanX DD-
dipeptidase activity with increasing vancomycin concentrations [144]. In contrast, D-
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Ala-D-Lac levels were essentially constant from 0 to 128 μg/ml vancomycin Figure 
45. The observation of flat D-Ala-D-Lac levels in response to increasing vancomycin 
concentrations is, however, somewhat surprising given that VanH and VanA—which 
encode for the D-Lac dehydrogenase and D-Ala-D-Lac ligase necessary for D-Ala-D-
Lac synthesis—are part of the VanA gene cluster, which also encodes for VanX, the 
D-Ala-D-Ala dipeptidase necessary for D-Ala-D-Ala hydrolysis [145]. The general 
presumption is that the expression of these three genes would be coregulated in 
response to vancomycin [144]. However, the data in Figure 45 clearly show a 
decrease in D-Ala-D-Ala concentration in response to vancomycin, demonstrating 
induction of VanX dipeptidase activity without a commensurate increase in D-Ala-D-
Lac levels. To determine whether there was a separate non-VanA process that could 
produce the background levels of D-Ala-D-Lac observed, vancomycin-sensitive 
Enterococcus faecium (VSE, ATCC BAA-2127) was assayed for D-Ala-D-Lac. No 
detectible D-Ala-D-Lac was found. The LOD for D-Ala-D-Lac is 0.60 pmol, and the D-
Ala-D-Lac level in VRE extracts was 4 pmol, so there is at least 7 times less D-Ala-D-
Lac in VSE than in VRE. These observations suggest that the regulation of gene 
expression in the VanA gene cluster is more complex than anticipated previously. 
This method was then demonstrated for the quantitation of these key 
metabolites in VRE. Measured levels of the internal standard (13C3-D-Ala) were 
highly reproducible Figure 45, demonstrating low experimental error in the 
extraction, derivatization, and LC-MS/MS steps. The variation observed in the raw L-
Ala and D-Ala levels appeared correlated Figure 45, which suggests that variation in 
these metabolites was due to differences in cultures before addition of the internal 
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standard (13C3-D-Ala). The observed variation was also uncorrelated with the cell 
density (OD at 600 nm) at the time of harvesting (data not shown). Normalization of 
the D-Ala, D-Ala-D-Ala, and D-Ala-D-Lac levels using L-Ala levels (a core metabolite) 
gives the results shown in Figure 46, which shows greatly reduced variation (σ2D-Ala 
in panel A = 1290 pmol2, and σ2D-Ala in panel B = 140 pmol2). Exposure to 
vancomycin results in a concentration dependent lowering of the D-Ala-D-Ala level 
Figure 45, with a midpoint around 0.06 µg/mL of vancomycin. This decrease in D-
Ala-D-Ala levels is consistent with induction of the VanX DD-dipeptidase activity with 
increasing vancomycin concentration [144]. In contrast, D-Ala-D-Lac levels were 
essentially constant from 0 – 128 µg/mL vancomycin Figure 45.  
Summary: The analytical method described above extends the utility of a 
Marfey’s reagent derivatization strategy for amino acid [140]  and dipeptide [140, 
146] quantitation, to the key depsipeptide intermediate in the most common types of 
vancomycin resistance [42-43]. This analytical method is demonstrated for 
characterizing the alanine branch metabolite profile in response to varied 
vancomycin concentration in VRE. The D-Ala-D-Ala level dropped substantially in 
response to increasing vancomycin concentration with a midpoint of ~0.06 µg/Ml 
Figure 45. In contrast, D-Ala-D-Lac was constant over the same vancomycin range, 
and present even in the absence of vancomycin/. This assay will be useful for 
studies of vancomycin-induced resistance, and for the discovery and development of 
new agents targeting vancomycin resistance in VRE. 
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CHAPTER 5 
DESIGNER LINKERS: MODEL REACTIONS AND LINEAR FREE ENERGY 
RELATIONSHIPS IN THE REACTIVITIY AND DESIGN OF SOLID-PHASE 
LINKERS 
Introduction  
The twentieth century has witnessed extraordinary developments in 
techniques for the synthesis of peptides and peptide mimetics. These techniques 
can be sub-divided into two main categories, “solution” and “solid-phase”. The 
various methods for synthesis in solution phase have been summarized in 
numerous monographs and reviews [147-149]. Unfortunately these methods are 
quite tedious and time consuming, and require considerable expertise, largely due to 
the unpredictable solubility characteristics of intermediates. In solution phase 
synthesis, purification and characterization are required after each step, and the 
solubility of the peptide worsens and becomes more unpredictable with increased 
chain length. Recognizing these limitations, R.B. Merrifield of Rockefeller University 
conceived the alternative solid-phase approach in 1959. In various publications 
Merrifield demonstrated the feasibility of the solid-phase approach for both manual 
and automated peptide synthesis [150-155]. Solid phase peptide synthesis (SPPS) 
has become a routine tool for the systematic exploration of biological and physical 
properties of peptides, and provided a basis for the development of combinatorial 
chemistry and solid-phase organic chemistry [103, 107, 156]. SPPS in the classical 
C-to-N direction is now a well-developed process. There is still considerable ongoing 
research in this area, with significant recent advances in the areas of protecting 
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groups (reviewed in [157-158]) coupling agents and methods (reviewed in [159]), 
strategies for assembling very large peptides from smaller building blocks using 
various ligation strategies (reviewed in [160]), strategies for attaching nascent 
peptide chain through the peptide backbone [161], and solid-phase methods for 
preparing C-terminally modified peptides [162].  
Overview of Boc and Fmoc approaches 
Two types of chemistry are commonly used for classical C-to-N SPPS, which 
differ based on the nature of the amine protecting group; Boc chemistry [163] and 
Fmoc chemistry [164-165] (Fig. 1). There are a number of common steps in 
traditional peptide synthesis: loading the first amine protected amino acid residue 
onto the resin through its carboxyl group, deprotection of the amine protecting group, 
and coupling with the next amine protected amino acid residue. Repeating the 
deprotection and coupling steps with the desired amino acid residues provides the 
final peptide fragment, with side chains protected, attached to the resin. The peptide-
resin attachment and side chain protecting groups are then removed to provide the 
desired peptide cleaved from the resin. Boc chemistry uses moderately acidic 
trifluoroacetic acid (TFA) to remove the Boc protecting group, whereas Fmoc 
chemistry generally uses the weak secondary amine base piperidine to remove the 
Fmoc protecting group. The resin attachment and side chain protecting groups in 
standard Boc chemistry can be cleaved with anhydrous HF, trifluoromethanesulfonic 
acid/TFA (TFMSA/TFA) mixtures, or HBr/TFA mixtures, whereas with Fmoc 
chemistry more acid labile resins and side chain protecting groups are used which 
can be cleaved with TFA. Auxiliary reagents and different cleavage protocols are 
 105 
 
often required to minimize side reactions, and to remove specific side chain 
protecting groups from the peptide (reviewed in [166]). 
A number of variables affect the success of any SPPS effort and must be 
considered during its planning and execution. Important choices that influence the 
overall outcome of a synthesis include the nature of the solid support, coupling 
chemistries, protection scheme, cleavage conditions, and the linkage for anchoring 
the peptide to the support.  
Resins for Boc SPPS (Figure 47) 
 Much of the original work in peptide synthesis was performed with Boc amino 
acids loaded onto hydroxymethyl (HM) polystyrene through an ester linkage (Fig. 2). 
After peptide synthesis is complete, the benzyl-O attachment bond is broken by use 
of relatively strong acid such as anhydrous HF, TFMSA/TFA, or HBr/TFA. Significant 
losses of peptide were observed on HM resins during repetitive deprotection of Boc 
groups with TFA, which led to the introduction of the more acid stable PAM (4-
(oxymethyl)-phenylacetamidomethyl) resin [167]. The benzyl-O bond in PAM resin is 
stabilized to acid relative to HM polystyrene by the electron withdrawing CO-CH2- 
group. In many applications it is desirable to prepare peptides with a C-terminal 
amide in place of a C-terminal carboxyl group, which led to the introduction of BHA 
(benzhydrylamine) resin [168]. The second benzene ring further stabilizes the benzyl 
cation generated during acidolysis, which is necessary since it is harder to acidically 
cleave the benzyl-N bond than the benzyl-O bond. After loading the first residue, 
peptide synthesis is performed following standard Boc protocols, and the peptide 
cleaved from the resin with a strong acid. Using BHA resin, it was observed that this 
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resin often gave low yields of product peptides due to inefficient cleavage of the 
benzyl-N bond. Substitution of this resin with the relatively weakly electron donating 
methyl group lead to the development of the more acid sensitive 
methylbenzhydrylamine (MBHA) resin [169], which is cleaved more efficiently with 
strong acids. 
Resins for Fmoc SPPS 
For Fmoc-based peptide synthesis, which uses the weak secondary amine 
base piperidine to remove the Fmoc protecting group, resins have been developed 
which allow the peptide to be cleaved from the resin with TFA, a considerably milder 
and easier to use reagent than HF or TFMSA/TFA. For carboxyl terminated peptides 
a p-alkoxybenzyl alcohol (Wang resin) is used [170], where the relatively strongly 
electron donating p-alkoxy substituent increases the acid sensitivity of the benzyl-O-
peptide attachment relative to the analogous HM resin used in Boc chemistry Figure 
47. For preparation of C-terminal amides, even more acid labile Rink amide [171] or 
PAL [172] resins can be used which allow the benzyl-N bond to be cleaved with 
TFA. Many other resins have been synthesized and tested for peptide synthesis and 
solid phase organic synthesis applications (reviewed in [173-174]). 
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Figure 47. Standard resins for Boc and Fmoc SPPS. 
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Anchoring 
 Regardless of the structure and nature of the polymeric support chosen, it 
must contain appropriate functional groups, e.g., amino, hydroxyl, chloromethyl, or 
other functionality, onto which the first amino acid can be anchored. Nearly fifty 
functionalization methods have been developed [175]. Later, some advantages of 
the handle approaches for anchoring have been recognized [167, 176-177]. 
Handles are nothing but bifunctional spacers that on one end feature a smoothly 
cleavable protecting group, and on the other end allow coupling to a previously 
functionalized support. Thus, handles serve to link the first amino acid to the resin 
in two distinct steps [178-180] and thereby afford maximal control over this 
essential step of the synthesis. 
Side chain protecting groups 
 Side protecting groups are an important aspect of solid phase peptide 
chemistry (reviewed in [157]). For Boc chemistry-based synthesis, where the peptide 
is cleaved from the resin with strong acids such as TFMSA/TFA, amine (Lys), 
carboxyl (Glu and Asp) groups, and hydroxyl (Ser, Thr, and Tyr) are generally 
protected with benzyl based protecting groups (Cbz, benzyl esters, and benzyl 
ethers respectively) which are simultaneously removed from the peptide during 
cleavage from the resin. Chlorine or Br substituted benzyl groups (Cl-Cbz; Br-Bzl) 
are more acid stable due to electron withdrawal by the halogen and are generally 
preferable as Lys and Tyr protecting groups respectively, especially for longer 
peptides. Alternatively, the more acid sensitive pMeO-Bzl or trityl protecting groups 
are preferred for Cys residues. Similarly strong acid (TFMSA/TFA) sensitive 
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protecting groups are used for other amino acids Table 7. Alternative selections of 
protecting groups are available if alternative HF, HBr, or TMSOTf cleavage protocols 
are to be employed. For Fmoc chemistry-based synthesis, where the peptide is 
cleaved from the resin with the moderately acidic TFA, amine and carboxylic acid 
functional groups are protected with t-butyl based protecting groups (Boc and t-butyl 
esters). Similarly moderate acid sensitive protecting groups are used for other 
functional groups. For both Boc and Fmoc-based syntheses, it is possible to cleave 
and deprotect simple (low amounts of side chain protecting groups) peptides from 
the resin using simple cleavage mixture, whereas more complex peptides often 
require additional scavengers or treatment to obtain good products. 
Coupling reactions 
The most important step in solid-phase peptide synthesis is the systematic 
elaboration of the growing peptide chain. This involves deprotection and coupling 
cycles. The temporary protecting group such as Boc or Fmoc is removed by 
acidolysis or base treatment to liberate the Nα-amine of the peptide resin. Then the 
α amine is neutralized with a tertiary amine such as diisopropylethylamine and the 
free amine of the resin-bound amino acid is ready to couple with a second 
protected amino acid. The latter must be activated for the reaction to occur. There 
are two major categories of activation. The first one is preactivation and the other 
one is in situ activation. In the former, the Cα- carboxyl of a protected amino acid is 
activated selectively to give a reasonably stable derivative, and in a separate step 
is reacted with an amine. In the later, an amine, carboxylic acid, and condensing 
agent are mixed together simultaneously to form an amide bond in situ. The 
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simplest and most often used procedure is activation with N,N’-
dicyclohexylcarbodiimide (DCC). N,N’-diisopropylcarbodiimide (DIC or DIPCDI) is 
even more convenient to use because of handling considerations and the improved 
solubility of the corresponding urea. Several side reactions are possible when 
carbodiimides are used. The majority of these side reactions may be circumvented 
by the addition of additives (1-hydroxybenzotriazole (HOBt) [181] or 1-hydroxy-7-
azabenzotriazole (3-hydroxy-3H-1,2,3-triazolo-[4,5-b] pyridine)(HOAt) [182], which 
react with the O-acylurea to form a less reactive but still effective acylating agent. 
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Table 7. Side chain protected amino acids suitable for Boc or Fmoc chemistry 
 
Boc-AA  
TFMSA cleavagea 
 
Fmoc-AA  
TFA cleavageb 
 
Arg(Mts)c 
Asp(OBzl) 
Cys(pMeOBzl) 
Glu(OBzl) 
His(Bom) 
Lys(2-Cl-Cbz) 
Met(O)d 
Ser(Bzl) 
Thr(Bzl) 
Trp(For)d 
Tyr(2-Br-Bzl) 
 
Arg(Pmc) 
Asp(OtBu) 
Cys(Trt) 
Glu(OtBu) 
His(Trt) 
Lys(Boc) 
 
Ser(tBu) 
Thr(tBu) 
Trp(Boc) 
Tyr(tBu) 
 
a For simple peptides 10% TFMSA in TFA can be used. To minimize side 
reactions in more complex peptides a scavenger cocktail can be used 
depending on the nature of the peptide. Typically, for 1x of resin,  
thioanisol/ethanedithiol (4x/2x), TFA (10x), and then TFMSA (2x) are added.  
b For standard cleavage reactions 95 % TFA, 2.5 % triisopropylsilane, 2.5 % 
H2O can be used. To minimize side reactions a scavenger cocktail can be used 
depending on the nature of the peptide. Typically, for 1x of resin, add an 8-10 
fold excess of 80% TFA, 5% thioanisol, 5% H2O, 3% ethanedithiol, 1% 
triisopropylsilane.  
c Abbreviations: Mts - Mesitylene(2,4,6-trimethylbenzene)sulfonate; Pmc - 
2,2,5,7,8-pentamethylchroman-6-sulfononate; Bom - benzyloxymethyl; Trt - trityl; 
For - formate. Other abbreviations are fairly standard. 
d Deprotected using a low-high TFMSA procedure. 
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 Recently some in situ coupling reagents have gained popularity. These 
include phosphonium salts as well as uronium salts. The most widely used salts 
include N-[(1H-benzotriazol-1-yl)(dimethylamino)methylene]-N-
methylmethanaminium hexafluorophosphate N-oxide (HBTU), N-[(dimethylamino)-
1H-1,2,3-triazolo-[4,5b]pyridine-1-yl-methylene]-N- methylmethanaminium 
hexafluorophosphate N-oxide (HATU) [182]. These reagents react with the 
carboxylate of an amino acid to form an active ester intermediate. These 
phosphonium and uronium salts have low reactivity with amino groups and are 
therefore well suited to in situ coupling protocols. To extend the peptide chain, 
deprotection, neutralization and coupling steps need to be repeated until the 
desired sequence has been synthesized. 
Cleavage from the resin  
Once the desired sequence has been synthesized, the complete peptide is 
deprotected and cleaved from the resin. Multiple options are available to cleave the 
bond connecting the peptide to the handle. These include acid, base [183-185], 
fluoride ion, Pdº [186], and light (hv) [175, 178, 180, 187-189]. Acid-labile handles 
are prevalent and can be divided further into those cleaved by strong acid (e.g., 
HF-scavengers), moderate acid  (e.g., trifluromethanesulfonic acid in TFA) [190], 
and mild acid (e.g., using very low percentage of TFA). The cleavage can be 
conducted to retain the permanent side chain protecting groups, and thus yield 
protected segments suitable for further condensation, or for later deblocking in 
solution [183, 191]. Most commonly the final deprotection of side chains is carried 
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out simultaneously with cleavage so that the released product is completely 
deprotected peptide [192]. 
Methods which allow for the synthesis of C-terminally modified peptides 
Normal SPPS in the C-to-N direction allows N-terminally modified peptides to 
be synthesized, but does not in its standard format allow for modification of the 
chemically versatile C-terminus since it is attached to the resin. Substantial effort 
has been devoted to addressing this deficiency. Such efforts can be divided into 
three groups; efforts based on C-terminal functional group specific attachment, 
efforts to develop effective methods for inverse (N-to-C) SPPS (ISPPS), and efforts 
to attach the C-terminal residue through its backbone amide nitrogen (Backbone 
Amide Linker (BAL) strategy), thereby providing the C-terminal carboxyl group for 
further elaboration. A short description of each follows. 
C-terminally modified peptide mimetics can be prepared through the use of 
functional group specific attachment strategies for the C-terminal residue which 
allows the C-terminal mimetic to be obtained upon cleavage from the resin. In this 
approach the peptide backbone is synthesized using classic C-to-N synthesis 
methods (Fmoc or Boc). Libraries with an aldehyde C-terminus have been prepared 
by an aldehyde-semicarbazone attachment strategy followed by traditional C-to-N 
peptide synthesis [193]. Specific attachment strategies have also been developed 
for peptide hydroxamic acids [194], and peptide alcohols [195]. Although suitable for 
a few C-terminial functional groups, the functional group specific attachment strategy 
lacks flexibility and generality. 
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It has long been recognized that a general approach for N-to-C solid-phase 
peptide synthesis (ISPPS) would be desirable, especially for the synthesis of 
C-terminally modified peptides [162]. ISPPS was first suggested by Letsinger & 
Kornet [196]. A number of investigations on strategies for ISPPS have been 
described, including based on the use of amino acid hydrazides [197], amino acid 
9-fluorenylmethyl (Fm) esters [198], amino acid tri-tert-butyloxysilyl esters [199], and 
amino acid allyl esters [200]. These approaches all suffer from limitations, including 
the general lack of availability of suitable monomers. The strategy we have 
developed for ISPPS is based on amino acid t-butyl esters [201-203].  t-Butyl esters 
have many advantages for ISPPS, including that they are stable, commercially 
available, and the synthesis of commercially unavailable monomers is 
straightforward. The t-butyl ester strategy also has the benefit that this approach is 
exactly the reverse of the well-developed Boc strategy for normal C-to-N peptide 
synthesis, and the extensive knowledge of side chain protection and other chemical 
details can be transferred from Boc-based SPPS to t-butyl ester-based ISPPS. 
Another approach to the preparation of C-terminally modified peptide 
mimetics is via a backbone amide linker (BAL) attachment strategy (reviewed in 
[204]). In this approach the first residue is attached to the resin through its amino 
group as a secondary amine, followed by Fmoc [205-207] or Boc [208-209] based 
synthesis of the peptide, selective protection/deprotection of the C-terminal carboxyl 
group, elaboration of the C-terminus into the desired functional group, and finally 
cleavage from the resin. 
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Overview of peptide derived agents (PDAs) 
A wide variety of both naturally occurring and man-made PDAs are known. 
Many of these are useful drugs, and others are potent natural toxins. There is 
currently great interest in PDAs given their potential for the development of new 
drugs and bioactive agents [210-212]. There has also been increasing interest in 
PDAs as components for nanotechnology [210, 213-215]. There are a very large 
number of known PDAs agents, and a complete list cannot be presented here. A 
representative selection of cyclic natural PDAs is provided below. The agents 
included are agents for which a versatile ISPPS approach could be useful in 
improving or redirecting their biological activity.  
Bacitracin is a group of at least 10 closely related peptides isolated from 
Bacillus subtilis Figure 48. The most active constituent is Bacitracin A. Bacitracin 
inhibits cell wall biosynthesis by binding to C55-isoprenyl pyrophosphate [216] 
reviewed in [217], an intermediate in bacterial cell wall biosynthesis. It is generally 
used topically, but can be administered parenterally to treat serious infections [218-
219].  A solid-phase synthesis of bacitracin has not been reported to our knowledge, 
but could allow for the optimization of its antibacterial activity and minimization of its 
nephrotoxicity. 
 Capreomycin is a mixture of two closely related cyclic peptide 
antibiotics, which is used as a second line tuberculostatic agent Figure 49. It acts by 
inhibiting protein biosynthesis [220]. It is used as a second line agent due to toxicity, 
which mainly involves disturbances to electrolyte balance. Several solution phase 
syntheses of this antibiotic have been reported as a basis for structure function 
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studies [221] and references therein, the most recent of which provided the desired 
product in only 2% overall yield after 27 steps. A solid-phase synthesis of 
capreomycin has not been reported to our knowledge, but could be useful for the 
optimization of its anti-mycobacterial activity and minimization of toxicity. 
Marine natural product peptides with anticancer activity. There have been a 
large number of peptide natural products derived from marine sources which have 
demonstrated anticancer activity, with a number having entered clinical trials 
including didemnin, hemiasterlin, dolastatins, cemadotin, soblidotin, aplidine, and 
kahalalide F [211-212]. These compounds have a diverse range of structures, and 
exert their effects through a variety of mechanisms. Kahalalide F is a representative 
example. It is cyclic peptide first identified in a marine mollusk [222], and later 
determined to be produced by an alga and taken up by the mollusk during feeding 
Figure 50 [223]. A solid-phase synthesis of Kahalalide F has been reported [224]. 
Alpha-Amanitin. Alpha-amanitin is a highly toxic bicyclic octapeptide found in 
the Amanita phalloides (Death Cap) and Destroying Angel mushrooms Figure 51 
[225]. After ingestion it is absorbed, travels to the liver where it enters cells, and 
binds to and inhibits RNA polymerase II. This is often lethal, and is untreatable 
except with an emergency liver transplant. The structure of amanitin complexed with 
RNA polymerase II is known [226]. Amanitin is of interest as an example of a peptide 
agent which is orally available and which reaches an intercellular target. 
Redesigning this agent to be non-toxic, and to target other processes, offers 
potential for the development of novel peptide-based therapeutic agents. 
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Figure 48. Structure of Bacitracin A. Adapted from Toscano et.al 1982.  
 
 
 
 
 
 
 
 
 
 
Figure 49. Structure of Capreomycin IA and IB. Adapted from DeMong D.E. et. al. 
2003. 
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Figure 50. Structure of Kahalalide F. Adapted from Hamann M.T et. al. 2001. 
 
Figure 51. Structure of Alpha-Amanitin. Adapted from Bushnell D.A. et. al. 2002. 
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Hammett equation and constants 
The Hammett equation was introduced by Hammett in 1937 and has been 
established as the most general and simplest approach to describe structure-
reactivity relationships in organic reactions [227]. The Hammett equation is based on 
the ionization of benzoic acids in water at 25 oC Figure 52 and is expressed as 
Log(KX/KH) = ρσ 
Where KX and KH are the ionization constants of meta- or para- substituted and 
unsubstituted aromatic compounds, respectively, σ is the substituent constant, and ρ 
is the reaction constant.  
When rate constants are involved the Hammett equation takes the form of 
Log(kX/kH) = ρσ 
Where kX and kH are the rate constants of meta- or para- substituted and 
unsubstituted aromatic compounds, respectively. 
OH
O
X
O
O
X
 H
Kx
 
Figure 52. Ionization of benzoic acids. 
σ constants obtained from the ionization of aromatic compounds in solution can 
successfully predict the ionization and rate constants for a wide variety of chemical 
reactions. Different reactions show different substituent sensitivities, which led to the 
use of alternative substituent constants (σ+) were used for better correlationed with 
reactions proceeding through benzyl cations. The σ+ constants are determined using 
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the new standard reaction of hydrolysis of t-cumyl chlorides in 90 % aqueous 
acetone (90A) at 25 oC Figure 53. 
C(CH3)2Cl
X
H2O
C(CH3)2OH
X HCl
C
CH3
CH3
X
Cl
H2O
90A, 25C
 
Figure 53. Hydrolysis of t-cumyl chlorides. 
 
 
Table 8. Some Hammett σ+p and σm constants from published standard tables. 
  
Substituent σ+p σm 
I 0.13 0.35 
Br 0.15 0.39 
Cl 0.11 0.37 
F -0.07 0.34 
C6H5 -0.21 0.05 
CH3 -0.31 -0.06 
SCH3 -0.6 0.15 
OCH3 -0.65 0.11 
OH -0.92 0.13 
NH2 -1.3 -0.16 
N(CH3)2 -1.7 -0.15 
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Overall Rationale 
 It would be useful for solid-phase PDA synthesis to have a versatile and 
general solid-phase method for bidirectional solid-phase peptide synthesis (BSPPS). 
Several features would be desirable in such a technology. 1) Solid-phase 
attachment of the nascent peptide through a backbone amide attachment. This 
would allow for the attachment of nearly any amino acid residue (except for proline 
and other secondary amines), and provide maximum flexibility in designing 
syntheses. 2) Chain extension in the C-to-N direction (classical SPPS) and/or in the 
N-to-C direction (inverse SPPS (ISPPS)) (bidirectional SPPS; BSPPS). This would 
provide maximum flexibility in the design and execution of PDA syntheses. These 
two target features would provide a technology of wide application in areas including 
drug discovery, chemical biology, and nanotechnology. It wasthe goal of this study to 
develop and test backbone attachemtn strategyies compatible with our t-butyl ester 
approach to ISPPS as the basis for such a general and flexible approach to PDA 
synthesis. The goal of the proposed effort will be to identify backbone amide 
attachment linkers with the appropriate chemical stability for BSPPS, and to then 
demonstrate an effective method for BSPPS using amino acid t-butyl esters for 
ISPPS, Fmoc amino acids for SPPS, and the use of the Dde group for N-terminal 
protection during ISPPS cycles. The experimental strategy for the overall rationale is 
as follow 
1) Obtain commercially available 4-hydroxy benzaldehyde compounds 
2) Do model reactions i.e loading of acetate or butyrate linker on the 
benzaldehyde compounds, loading of Phe-OtBu and capping the amine 
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group on Phe-OtBu with acetic anhydride. Deprotect the OtBu and purify 
the compounds. 
3) Check the stability of the linker to deprotection of OtBu with 25%TFA/DCM 
and cleaving the Ac-Phe with 5% HBr/TFA. Determine the rate constant 
for this cleaving reaction. 
4) Using the Hammett constants and the rate constants determine the 
reaction constant rho and also identify the linker with right stability for 
performing the ISPPS and be able to cleave using 5% HBr/TFA 
5) Load the linker onto the resin and demonstrate the ISPPS using amino 
acid t-butyl esters. 
6) Demonstrate SPPS using fmoc amino acids. 
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Experimental 
Materials: Aminomethylated polystyrene (1.17 mmol/g, 70-90 mesh) was 
purchased from Novabiochem AG (Gibbstown, NJ), and amino acid t-butyl esters 
were purchased from Bachem AG (King of Prussia, PA). HATU (O-(7-
azabenzotriazol-1-yl-N,N,N’,N’-tetramethyluroniumhexafluorophosphate), DIPEA 
(N,N-Diisopropylethylamine), HBr (Hydrogen bromide, 33 wt.% solution in acetic 
acid), TMP (2,4,6-trimethylpyridine), TFA (trifluoroacetic acid) and TFMSA 
(trifluoromethane sulfonic acid), anhydrous DMF (N,N-dimethyformamide), and 
anhydrous DCM (dichloromethane) were purchased from Sigma-Aldrich (Milwaukee, 
WI). All chemicals purchased were of reagent grade. 
Sovents: All the solvents used during solid phase synthesis are anhydrous 
and dried over 4Ao molecular sieves. 
Preparative HPLC: Preparative HPLC was performed on a Hewlett-Packard 
series 1050 system equipped with a diode array detector, fraction collector (Gilson 
Model 203) and a Econosil C18 column (22.0 x 250 mm, 10 µm particles). 
Chromatographic conditions used are gradient elution flow rate of 5.0 ml/min; 100% 
solvent A (0.1% TFA in water) for 5 min, then 0% to 100% of solvent B (0.1% TFA in 
30:70 water:acetonitrile) in 55 min, and 0% to 100% of solvent C (0.1 % TFA in 
acetonitrile) in next 10 min and a linear gradient of 100% solvent A for 10 min. 
Eluting compounds were collected in fraction collector (Gilson Model 203). The 
fractions were analyzed by LC-MS and the pure fractions were lyophilized and used 
for further experiments. 
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LC-MS Analysis: LC–MS analysis was carried out on an ABI 2000 Q-Trap 
mass spectrometer fitted with electro-spray ionization (ESI) source and interfaced to 
an Agilent 1100 series HPLC system equipped with a diode array detector. LC–MS 
was performed using a Nucleodur  C8 column (2.0 x 125 mm, 5 µm particles) and 
chromatographic conditions used are gradient elution with a flow rate of 0.3 ml/min; 
100% solvent A (0.1% TFA in water) for 2 min, 0% to 100% of solvent B (0.1% TFA 
in 30:70 water:acetonitrile) in next 10 min, and 0% to 100% of solvent C (0.1 % TFA 
in acetonitrile) in next 3 min and then a linear gradient of 100% solvent A for 3 min. 
Solution phase model reactions  
The first set of model linkers were constructed as outlined in Figure 54 and Figure 
55. The substituents used on linkers were outlined in Table 9. These linkers were 
then tested for their acid stability using 25% TFA/DCM for 30 min. (OtBu 
deprotection conditions) and 5% HBr/TFA (peptide-resin cleavage conditions). The 
rate constants for the cleaving reaction with 5% HBr/TFA was determined for the 
linkers. The reaction constant ρ was determined using the rate constants and the 
Hammett constants of the linkers. Linkers with right acid stability i.e. stable during 
deprotection of OtBu with 25% TFA/DCM for 30 min. and which will be able to 
cleave the peptide with treatment of 5% HBr/TFA will be selected. These linkers will 
be loaded onto resin and ISPPS cycles performed to demonstrated their feasibility. 
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General synthesis procedure for butyrate and acetate connector based 
linkers: 
 
OH
OH
OH
O
OH
O
O
O
O
O
a
b
 
(a) ethyl 4-bromobutyrate, K2CO3, DMF; (b) methyl 2-bromoacetate, K2CO3, DMF; 
Figure 54. Scheme for loading acetate and butyrate linker onto benzaldehyde 
compounds 
 
1 eq of 4-hydroxy benzaldehyde and 1.1 eq of linker (ethyl 4-bromobutyrate 
for attaching butyrate linker and methyl 2-bromoacetate for attaching acetate linker) 
were dissolved in DMF, 1.1 eq of K2CO3 was added and the mixture was stirred 
overnight at rt (Figure 54). The reaction mixture was quenched with 4 eq of 1M HCl, 
extracted 3 times with ethyl acetate and back extracted once with 1M NaHCO3. The 
combined organic extracts were dried over MgSO4 and evaporated to dryness in 
vacuo. This was sufficiently pure for further use. To attach butyrate or acetate linker 
to different benzaldehydes, their respective 4-hydroxy benazaldehydes were used.  
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 (a) H-Phe-OtBu.HCl, DIPEA, NaCNBH3, DMF; (b) acetic anhydride, DIPEA, DMF; 
X,Y,Z substituents were outlined in Table 9. 
Figure 55. Scheme for loading H-Phe-OtBu.HCl and capping with acetic anhydride. 
 
 
Table 9. List of X,Y,Z substituents for the model compounds in Figure 55 
Comp. 
No. 
X Y (ortho) Z (ortho') 
1 CH2COOMe H,H H 
2 (CH2)3COOEt H,H H 
3 CH3 H,H H 
4 CH3 CH3 H 
5 (CH2)3COOEt CH3 H 
6 CH2COOMe CH3 CH3 
7 (CH2)3COOEt CH3 CH3 
8 CH2COOMe OCH3 H 
9 (CH2)3COOEt OCH3 H 
10 CH3 OCH3 H 
11 CH2COOMe OCH3 OCH3 
12 (CH2)3COOEt OCH3 OCH3 
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General Procedure for loading Phe-OtBu on solution phase linkers: 1 eq. of 
benzaldehyde linker was dissolved in andhyrous DMF (dried over 4Ao molecular 
sieves), 1 eq. of H-Phe-OtBu.HCl and 2 eq. of DIPEA (dried over 4Ao molecular 
sieves) were added to the reaction mixture and stirred for 15 min. To this mixture 
was added 1.5 eq. of NaCNBH3 and the mixture was stirred overnight at rt. The 
reaction mixture was diluted with water, 1M HCl added to pH 4, and the mixture was 
extracted 3 times with ethyl acetate the combined organic extracts back extracted 1x 
with NaOH, and with brine. The organic extract was dried over MgSO4, and 
evaporated to dryness in vacuo.  
Procedure for acetic anhydride capping on model compounds in solution 
phase: The Phe loaded model compound (1 eq.) was dissolved in andhydrous DMF 
(dried over 4Ao molecular sieves), 3 eq. of DIPEA (dried over 4Ao molecular sieves) 
and 3 eq. of acetic anhydride were added, and the reaction mixture was stirred 
overnight at rt Figure 55. The reaction mixture was quenched with 5 eq. of 1M 
NaHCO3 and stirred for 30 min, extracted 3 times with ethyl acetate and the 
combined organic extracts was back extracted 1x with 1M HCl. The organic extract 
was dried over MgSO4 and evaporated to dryness in vacuo.  
Deprotection of OtBu and cleaving AcPheCOOH: AcPheOtBu loaded model 
compound (40 mg) was treated with 25% TFA/DCM (2 mL) for 30 min and 
evaporated to dryness in vacuo to give AcPheCOOH loaded model compound 
Figure 60. This compound was purified on preparative HPLC. AcPheCOOH was 
cleaved from the model compound by treating with 5% HBr/TFA. 
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Rate constant determination: AcPheCOOH loaded benzaldehydes were 
treated with 5% HBr/TFA and samples were collected at 1, 5, 10, 30 mins, 1, 2, 4, 8, 
12, 24 hrs. Since HBr/TFA is volatile this treatment was done in a vial sealed with 
rubber cap and kept in a bigger vial fitted with MININERT valve Figure 56. The 
samples collected were analyzed using LC-MS and the area of the AcPheCOOH 
peak was determined. Plots of ln(area) vs time demonstrate first order kinetics and 
the rate constant k was determined from the slope of the plot. 
 
 
Figure 56. Vial setup for performing kinetics on model compounds with 5%HBr/TFA. 
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Preparation of solid phase attached linker 
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a) K2CO3, 1:1:1 mixture of H2O:MeOH:acetonitrile 
Figure 57. Scheme for saponification of ester group on the linker. 
 
Synthesis of 2-methyl-4-(5-oxyvalericacid)-benzaldehyde: 2-methyl-4-(5-oxy-
ethylvalerate)-benzaldehyde linker 2 (919 mg, 3.67 mmol) and K2CO3 (1.52 g, 11.01 
mmol) were dissolved in 1:1:1 mixture of H2O:MeOH:acetonitrile and stirred 
overnight at rt. The reaction mixture was made neutral by adding 1M HCl and 
rotovaped to remove the solvents (MeOH and acetonitrile). The reaction mixtures 
was extracted once with ether, acidified to pH 4 with 1M HCl and extracted with ethyl 
acetate (3 X 30 mL). The combined organic extracts were dried over MgSO4 and 
evaporated to dryness in vacuo yielding a yellow solid. Yield (653 mg, 80%).  
Test conditions for acidolysis of Ac-Phe loaded 2-methyl-4-(5-oxyvalericacid)-
benzaldehyde model linker: 600 µL of 10 mM solution of 2-methyl-4-(5-
oxyvalericacid)-benzaldehyde was subjected to various test treatments; 25% 
TFA/DCM, 37.5% TFA/DCM, 50% TFA/DCM, 75% TFA/DCM, 100% TFA/DCM, 
95% TFA/H2O, 10% TFMSA/TFA, 5% HBr/TFA. Samples (10 µL) were collected at 
regular time intervals (15 min, 30 min, 1 hr, 2 hr, 4 hr, 8 hr, 12 hr and 20 hr), diluted 
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in 90 µL of ACN:H2O, and analyzed on LC/MS. The rate constants and half-life’s of 
each testing condition were determined and tabulated in Table 15. 
Loading of linker onto resin and demonstration of ISPPS 
 
NH2
+ O
H O
H
N
O
O
H O
O
HO
H O
a
 
(a) HATU, DIPEA,  DMF; 
Figure 58. Scheme for loading 2-methyl-4-(5-oxyvaleric acid)benzaldehyde linker 
onto the amino methyl polystyrene resin. 
 
2-methyl-4-(5-oxyvalericacid)-benzaldehyde linker attachement onto resin: 
Aminomethylated polystyrene resin (loading 0.78 mmol g-1, 100-200 mesh) was 
swollen in DMF for 2 hrs and then washed with DMF. 2-methyl-4-(5-oxyvalericacid)-
benzaldehyde linker  (86.7 mg, 0.39 mmol) and O-(7-azabenzotriazol-1-yl)-
N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) (148.3 mg, 0.39 mmol) 
were dissolved in DMF (1 mL), DIPEA ( 140 µL, 0.78 mmol) was added, and the 
clear solution was immediately added to resin (100 mg, 0.078 mmol). The 
suspension was shaken for 16 hrs at rt. The resin was washed with 3 X DCM (700 
µL), 3 X DMF (700 µL) and vacuum dried. A solution of acetic anhydride (22.1 µL, 
0.23 mmol) and DIPEA (40.7 µL, 0.23 mmol) in DMF was stirred with resin for 12 hrs 
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to cap unreacted amino groups. The resin was washed 3 x DCM (700 µL), 3 x DMF 
(700 µL) and vacuum dried. The anchored 2-methyl-4-(5-oxyvalericacid)-
benzaldehyde linker can be seen in Figure 58. 
 
 
NH2-AA1-OtBu NH-AA1-OtBu
OH
N-AA1-OtBu
Ac
Capping
N-AA1-COOH
Ac
Deprotectb
N-AA1-AA2-OtBu
Ac
N-AA1-AA2-AA3-OtBu
Ac
Couple
Deprotect,
  Couple
Deprotect,
  Cleave
NH-AA1-AA2-AA3-COOHAc
c
b,c
b,d
aNaCNBH3
 
(a) Ac2O, DIPEA, DMF; (b) 25% TFA/DCM; (c) HATU, amino acid, TMP, DMF;   
(d) 5% HBr/TFA 
Figure 59. Scheme for amino acid t-butyl ester based ISPPS. 
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Table 10. Amino acid t-butyl ester based ISPPS protocol. 
 
 
 
 
 
 
 
 
 
 
 
Description 
 
Reagent 
 
Repetition 
and Duration 
OtBu  
Deprotection 
10% TFA/DCM  
25% TFA/DCM 
1  5 s 
1  30 min 
Washes 
DCM 
NMP 
DCM 
3  5 s 
2  5 s 
3  5 s 
Activation 
/Coupling 
5 eq. HATU 
5 eq. AA-OtBu·HCl 
10 eq. TMP in DMF 
12 h 
Washes  
DCM 
DMF 
3  5 s 
3  5 s 
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Loading of the first amino acid by reductive amination: The overall synthesis 
strategy is outlined in Figure 59. To load the first amino acid (Phe), a solution of H-
Phe-OtBu.HCl (80.2 mg, 0.31 mmol) and DIPEA (108.7 µL, 0.62 mmol) in DMF (750 
µL) was added to the resin (100 mg, 0.078 mmol). After shaking for 15 min, 
NaBH3CN (29.4 mg, 0.47 mmol) was added and shaken for 16 Hrs at rt. The resin 
was washed with 3 X DCM (700 µL) and 3 X DMF (700 µL) and vacuum dried.  
Capping: It was desirable to test the chemical sensitivity of different capping 
groups on sensitivity to cleavage (25% TFA/DCM and 5% HBr/TFA). After loading, 
the secondary amine of the resin attached HPhe-OtBu was capped with different 
capping reagents such as acetic anhydride, toluoyl chloride, isovaleryl chloride and 
benzoyl chloride. To cap the first amino acid (Phe), a solution of capping reagent (3 
eq.) and DIPEA (7.5 eq.) in 750 µL DCM was added to the resin and shaken for 12 
Hrs at rt. The resin was washed with 3 X DCM and 3 X DMF and vacuum dried. 
Amino Acid t-Butyl Ester-Based ISPPS: After loading, the t-butyl ester of the 
first residue was deprotected with 25% TFA/DCM, and synthesis cycles were 
performed as outlined in Table 10. 
Cleavage of peptides from resin: Peptide loaded resin sample (10 mg) was 
treated with 5% HBr/TFA for 8 Hr. The cleavage solution was sampled and analyzed 
by HPLC and LC/MS. Four tripeptides with acetic anhydride as capping group and 
Phe capped with different capping groups were synthesized Table 16 and Table 17. 
These peptides were analyzed by LC-MS for purity and yield and for amino acid 
racemization using Marfey’s reagent. 
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Amino acid racemization: The amount of racemization of amino acids in 
product peptides was determined by derivitization with Marfey’s reagent [107, 139]. 
A 2 μL aliquot of a 50 mM aqueous solution of the sample was hydrolyzed with 100 
μL 6 N HCl for 4 hours at 110 oC in sealed vials, and the hydrolyzed mixture dried 
under vacuum. To this was added 14.3 μL (5 eq per amino acid) of a 1% solution of 
Marfey’s reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine amide) in acetone, 4 μL of 1 
M NaHCO3 and 6 μL of water, and the mixture was kept at 35-40 oC for 90 min. The 
reaction was quenched by the addition of 4 μL of 1 M HCl. Solvent was removed 
under vacuum and the residue was dissolved in 400 μL of 1:1 acetonitrile and water 
containing 0.1% of TFA. A 10 μL injection was made for HPLC analysis.  
Results and Discussion 
Importance of solution phase model reactions: Several commercial resins 
were tried for the development of this approach but these resins were not stable to 
treatment of acids either for deprotection of OtBu with 25% TFA/DCM or cleaving of 
peptide with 5% HBr treatment. During treatments with these acid, part of the resin 
would cleave off or the peptide itself would come off it can be very difficult to 
determine exactly what is happening in a solid-phase reaction, especially when the 
resin attachment is involved, since a portion of the reaction products are solid-phase 
attached. Inability to characterize some of the fragments that we see after acid 
treatment complicates a full understanding of what is happening. To circumvent this 
limitation, model solution phase reactions were used to characterize different 
potential linker moieties as a prelude to performing the analogous reactions on the 
solid-phase. With an aim to develop a linker that would be stable to 25% TFA/DCM 
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treatment and cleave the peptide when treated with 5% HBr/TFA, several substituted 
benzaldehyde linkers were investigated for their acid stability using model solution 
phase reactions.  
Scheme of model cleaving reaction on solution phase: OtBu was deprotected 
from N-Acetyl-[2-methyl-4-(5-oxy-ethylvalerate)benzyl]-L-phenylalanine-OtBu by 
treating with 25% TFA/DCM for 30 mins. The resulting N-Acetyl-[2-methyl-4-(5-
oxyvalericacid)benzyl]-L-phenylalanine was then treated with 5% HBr/TFA for 24 hrs 
and samples were collected at 1, 5, 10, 30 mins, 1, 2, 4, 8, 12, 24 hrs and analyzed 
using LC-MS. The area of AcPheCOOH formed was determined. The rate constant 
of this reaction was obtained by plotting ln(area of AcPhe formed) vs time. Rate 
constants and t1/2 of the linkers were reported in Table 12. 
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Figure 60. Scheme of solution phase model cleaving reaction
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Table 11. Molecular weight confirmation and yields of linkers synthesized. 
    Mol Wt [M+H]+       
Comp. 
No. 
Compound Name Calcd Found 
Yield 
(%) 
Mass 
Spectrum 
HPLC 
Chromatogram 
1 N-Acetyl-[4-(5-oxy-methylbutyrate)benzyl]-L-
phenylalanine 
442.5 442.1 53 Figure 63 Figure 64 
2 N-Acetyl-[4-(5-oxy-ethylvalerate)benzyl]-L-
phenylalanine 
484.6 484.2 59 Figure 65 Figure 66 
3 N-Acetyl-[4-methoxylbenzyl]-L-phenylalanine 384.5 384.2 49 Figure 67 Figure 68 
4 N-Acetyl-[2-mehtyl-4-methoxylbenzyl]-L-
phenylalanine 
398.5 398.3 54 Figure 69 Figure 70 
5 N-Acetyl-[2-methyl-4-(5-oxy-ethylvalerate)benzyl]-L-
phenylalanine 
498.6 498.2 57 Figure 71 Figure 72 
6 N-Acetyl-[2,6-dimethyl-4-(5-oxy-
methylbutyrate)benzyl]-L-phenylalanine 
470.6 470.2 47 Figure 73 Figure 74 
7 N-Acetyl-[2,6-dimethyl-4-(5-oxy-
ethylvalerate)benzyl]-L-phenylalanine 
512.7 512.2 57 Figure 75 Figure 76 
8 N-Acetyl-[2-methoxy-4-(5-oxy-
methylbutyrate)benzyl]-L-phenylalanine 
472.5 472.4 54 Figure 77 Figure 78 
9 N-Acetyl-[2-methoxy-4-(5-oxy-ethylvalerate)benzyl]-
L-phenylalanine 
514.6 514.2 58 Figure 79 Figure 80 
10 N-Acetyl-[2-methoxy-4-methoxylbenzyl]-L-
phenylalanine 
414.5 414.2 51 Figure 81 Figure 82 
11 N-Acetyl-[2,6-dimethoxy-4-(5-oxy-
methylbutyrate)benzyl]-L-phenylalanine 
502.6 502.0 59 Figure 83 Figure 84 
12 N-Acetyl-[2,6-dimethoxy-4-(5-oxy-
ethylvalerate)benzyl]-L-phenylalanine 
544.7 543.4 49 Figure 85 Figure 86 
13 N-Acetyl-[4-(5-oxy-methylbutyrate)naphthyl]-L-
phenylalanine 
492.6 492.1 53 Figure 87 Figure 88 
14 N-Acetyl-[4-(5-oxy-ethylvalerate)naphthyl]-L-
phenylalanine 
534.7 534.2 52 Figure 89 Figure 90 
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Table 12. Half-lifes and rate constants of the linkers under 5%HBr/TFA treatment. 
Cmp.No. 
  
OR o,o' 
t1/2 
(hr) 
k (hr-1) SE 
  
1 Bz CH2COOMe H,H n/a n/a n/a 
2 
 
(CH2)3COOEt H,H 4.56 0.15 0.38 
3 
 
CH3 H,H 5.41 0.13 0.01 
4 
 
CH3 CH3 2.75 0.25 0.02 
5 
 
(CH2)3COOEt CH3 1.86 0.37 0 
6 
 
CH2COOMe CH3,CH3 1.55 0.45 0.01 
7 
 
(CH2)3COOEt CH3,CH3 0.68 1.02 0.11 
8 
 
CH2COOMe OCH3 1.76 0.39 0.03 
9 
 
(CH2)3COOEt OCH3 0.07 9.59 0.66 
10 
 
CH3 OCH3 0.07 9.6 0.4 
11 
 
CH2COOMe OCH3, OCH3 0.3 2.32 0.12 
12 
 
(CH2)3COOEt OCH3, OCH3 0.31 2.2 0.12 
       
       13 Nap CH2COOMe H,H 2.64 0.26 0.01 
14   (CH2)3COOEt H,H 0.19 3.62 0.2 
Bz=Benzaldehyde; Nap=Napthaldehyde; 
Calculation of σ+ values for different linkers: The σ+ values of individual 
substituent Me and OMe were obtained from published tables [228] and listed in 
Table 13. The σ+ values of individual substituent OAc and OBu were obtained by 
least squares. For substituents with unknown σ+ values, σ+ values were obtained by 
minimizing the sum of squares of the difference between observed k value and the 
best fit line for other compounds with known k values. The obtained σ+ values are 
reported in Table 13.    A plot between observed k value and predicted k value is 
shown in Figure 61.  The σ+ values for synthesized linkers were calculated by 
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summing up the individual σ+ values (Table 13) of all the substituents on the linker. 
The final σ+ values of the linkers were summarized in Table 14. 
 
Table 13.  σ+ values of individual substituents  
Substituent σ+   
Me -0.256 Lit. 
OMe -0.648 Lit. 
OCH2COOMe -0.305 Calc. 
O(CH2)3COOEt -0.86 Calc. 
Lit.=Literature; Calc.=Calculated; 
 
Table 14. σ+ values for different benzaldehyde linkers synthesized 
S.No.  OR o,o' σ+ 
  
1 Bz CH2COOMe H,H -0.305 
2 
 
(CH2)3COOEt H,H -0.86 
3 
 
CH3 H,H -0.648 
4 
 
CH3 CH3 -0.904 
5 
 
(CH2)3COOEt CH3 -1.116 
6 
 
CH2COOMe CH3,CH3 -0.817 
7 
 
(CH2)3COOEt CH3,CH3 -1.372 
8 
 
CH2COOMe OCH3 -0.953 
9 
 
(CH2)3COOEt OCH3 -1.508 
10 
 
CH3 OCH3 -1.296 
11 
 
CH2COOMe OCH3, OCH3 -1.601 
12   (CH2)3COOEt OCH3, OCH3 -2.156 
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Figure 61. Plot between observed k value and predicted k value for different linkers, 
and concensus best line. 
 
Plot showing Rho Calculation: linkers which fell on the straight line in Figure 
61 were chosen for calculating the ρ value. In other words linkers that fell on the 
concensus line for observed and predicted rate constans were chosen for calculating 
ρ value. The reaction constant ρ was obtained from the slope of the plot between the 
log(observed rate constant of the reaction with substituent) vs the σ+ of the 
substituents Figure 62.  The reaction constant ρ obtained was -1.1.  
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Figure 62. Plot between σ+ and log(kobs) for calculating Rho value. 
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Selection of final particular linker: To provide a suitable linker for BSPPS 
using our t-butyl ester strategy for ISPPS (N-to-C) and an Fmoc strategy for SPPS 
(C-to-N), it is necessary for the attachment to be stable to the TFA/DCM conditions 
used to deprotect t-butyl esters, and stable to the condition necessary to deprotect 
Fmoc and Dde groups. The attachment must also be cleavable using standard 
strong acid conditions such as TFMSA/TFA or HBr/TFA.  All the possible 
benzaldehyde linkers that are commercially available and which could provide the 
acid stability required for the envisioned application were procured and model 
solution phase reactions were done as shown in Figure 60. Half-life and rate 
constants for the cleaving step with 5% HBr/TFA were determined for the linkers and 
tableted in Table 12. During model solution phase reactions we have observed that 
the 4-methoxy benzaldehyde based linker (compound number 3 in Table 11) was 
too stable to acid treatment with 5% HBr/TFA and gave poor yields and incomplete 
cleavage. In contrast, 2, 4-dimethoxy-benzaldehyde based linker (compound 
number 10 in Table 11) was too easily cleaved even with the 25% TFA/DCM 
treatment that is needed to deprotect t-butyl esters. Among other linkers N-Acetyl-[2-
methyl-4-(5-oxy-ethylvalerate)benzyl]-L-phenylalanine (compound number 5 in 
Table 11) seemed to be the perfect linker with the right kind of acid stability. When 
treated with 25% TFA/DCM for 30 min. a small amount (less than 2%) of the Ac-Phe 
cleavage product was detected. This loss (cleavage) is small and indicates that the 
analogous 2-methyl-4-(5-oxyvalericacid)benzaldehyde based resin would be suitable 
for up to 12 synthesis cycles with greater than a 80% yield of the product peptide. 
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90% of the peptide cleavage can be done with 5% HBr/TFA in 6.2 Hrs and 99% of 
the peptide can be cleaved in 12.5 Hrs. The chemical reactivity of this linker was 
further examined with various concentrations of TFA in DCM and their rate constants 
and half-life’s were determined Table 15. The ability of this linker to be cleaved by 
an extended treatment with 100% TFA may provide a useful means to prepare 
protected peptide fragments (with a unprotected C-terminus) from the analogous 
resin, since Boc chemistry compatible side chain protecting groups should be stable 
to this treatment. 
Table 15. N-Acetyl-[2-methyl-4-(5-oxy-ethylvalerate)benzyl]-L-phenylalanine linker's 
cleavage rate for different acid treatments. 
Test Condition k (hr-1) t½  (Hrs) 
25% TFA/DCM 0.073 9.56 
37.5% TFA/DCM 0.076 9.17 
50% TFA/DCM 0.082 8.49 
75% TFA/DCM 0.094 7.39 
100% TFA/DCM 0.144 4.81 
95% TFA/H2O 0.122 5.67 
10% TFMSA/TFA 0.422 1.64 
5% HBr/TFA 0.435 1.59 
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Loading of linker onto resin: To load the 2-methyl-4-(5-oxyethylvalerate)-
benzaldehyde linker onto resin, the ethyl ester was saponified by K2CO3 in a 1:1:1 
mixture of H2O:EtOH:acetonitrile Figure 57. The deprotected linker was coupled to 
the α-amine of the aminomethyl polystyrene resin using HATU Figure 58. Any 
residual free amino groups was capped with acetic anhydride.  
Loading of first amino acid onto resin: The first amino acid was loaded onto 
the resin by reductive amination, followed by N-acylation Figure 59. The above 
outlined procedure was followed with Phe as the loaded residue and capped with 
acetic anhydride. Cleavage using 5% HBr/TFA and quantitation of Ac-Phe by HPLC 
with UV-Vis detection at of 260 nm demonstrated greater than 90% loading 
efficiency.  
Demonstration of ISPPS cycles: To demonstrate this linker for ISPPS, four 
acetic anhydride capped tripeptides were synthesized.  All these peptides were 
identified by LC-MS and were obtained in good yield and purity Table 16. Peptides 
were analyzed for the degree of amino acid racemization using Marfey’s reagent.  
No detectable levels of racemization was observed using this approach. This 
solution phase model reaction linker was capped with only acetic anhydride. Effect 
of different capping groups on the stability of the linker was checked on the solid 
phase by capping the first amino acid (Phe) with acetic anhydride, toluoyl chloride, 
isovaleryl chloride and benzoyl chloride.  OtBu was deprotected by treating with 25% 
TFA/DCM for 30 min. and the capped Phe was cleaved by treating with 5% HBr/TFA 
and analyzed by LC-MS Table 17.  Tolyoyl and benzoyl capping groups made the 
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linker more acid liable and during the deprotection of OtBu, indicative higher acid 
sensitivity with these capping groups.  
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Table 16. Molecular weight confirmation, purities, and yields of the synthesized 
peptides. 
  Product 
Mol Wt [M+H]+ 
    
Puritya Yieldb 
Calcd Found % % 
1 AcPheAlaGly 335.4 336.2 98 88 
2 AcPheLeuVal 419.5 420.4 95 80 
3 AcPheGlyVal 363.4 364.2 95 85 
4 AcPheAlaVal 377.4 377.0 88 81 
 
a Determined by HPLC of cleaved peptide 
b Determined by amount of peptide obtained after cleavage 
 
 
Table 17. Molecular weight confirmation of different capping groups and % cleavage 
during deprotection step. 
  Product 
Mol Wt [M+H]+ 
% Cleaved 
during 25% 
TFA/DCM 
treatment Calcd Found 
1 Ac-Phe 207.2 208.2 1 
2 Tolyoyl-Phe 283.3 284.2 9 
3 Isovaleryl L-Phe 249.3 250.2 1 
4 Benzoyl-Phe 269.3 270.2 6 
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Attempt to demonstrate BSPPS: To achieve maximum flexibility for PDA 
synthesis, it would be desirable to be able to perform chain extension reactions also 
in the C-to-N direction (SPPS). This will provide a common central core for the 
subsequent SPPS and ISPPS extension cycles The linker was attached to the resin 
by backbone amide link and then first amino acid Phe-OtBu was loaded by reductive 
amination. Then we tried to acylate the secondary amino group either with Fmoc-Ala 
or Dde-Ala. No acylation was observed with Fmoc-Ala and only very low percentage 
(20%) acylation was achieved with Dde-Ala, even after a second acylation. It has 
been published previously that acylation of the secondary amine of backbone 
attached amino acids was difficult by Jensen et. al. [38], who suggested some 
variations in standard acylation reaction conditions. We have tried the suggested 
variations like use of high ratio of DCM to DMF (9:1) and using acyl chloride as the 
acylating agent (Fmoc-Ala-Cl) but still no change was observed in acylation. Later 
the acylation was carried in a microwave reactor with optimized condition of prespin 
for 5 min., temperature of 150 o C for 1 Hr. No acylation was observed with Fmoc-
Ala, but with Dde-Ala 85% acylation found. This dipeptide Dde-Ala-Phe-OtBu 
provides a common central core for ISPPS and SPPS extension cycles. 
Deprotection of OtBu with 25% TFA/DCM for 30 min was tested. This deprotection 
solution was analyzed by LC-MS, and it was found that around 40% of the central 
core Dde-Ala-Phe was cleaved. To determine if this change in the acid sensitivity of 
the linker is due to the Dde group or not, the following steps were followed. The Dde 
group was deprotected with 5% Hydrazine for 1 hr, capped with acetic anhydride, 
and OtBu deprotected with 25% TFA/DCM. Analysis by LC-MS found that 40% of 
 148 
 
Ac-Ala-Phe was cleaved. Acylation of the secondary amino group with an amino 
acid made the linker more acid liable than with simple acylation (with acetyl or 
isovarleryl capping groups) and this linker 2-mehtyl-4-(5-oxyethylvalerate)-
benzaldehyde couldn’t be used for the demonstration of BSPPS. The most stable 
among the linkers in Table 12, 4-(5-oxy-methylbutyrate)benzaldehyde, was chosen 
and tried for demonstrating BSPPS. Deprotection of OtBu with 25% TFA/DCM still 
significantly cleaved the nascent peptide from the resin.  BSPPS demonstration with 
the linkers that were studied in this project was not possible due to the fact that the 
linker became more acid sensitive with the acylation of the secondary amino group 
and the central core dipeptide was getting cleaved during the deprotection of OtBu. 
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 +EMS: 13.855 min from Sample 4 (81) of DataSET1.wiff (Turbo Spray) Max. 1.1e7 cps.
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Figure 63. Mass spectrum of N-Acetyl-[4-(5-oxy-methylbutyrate)benzyl]-L-
phenylalanine (Cmp. No. 1). 
 
Figure 64. HPLC chromatogram of N-Acetyl-[4-(5-oxy-methylbutyrate)benzyl]-L-
phenylalanine (Cmp. No. 1). 
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 +EMS: 15.363 min from Sample 1 (80) of DataSET1.wiff (Turbo Spray) Max. 2.1e7 cps.
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Figure 65. Mass spectrum of N-Acetyl-[4-(5-oxy-ethylvalerate)benzyl]-L-
phenylalanine (Cmp. No. 2). 
 
 
Figure 66. HPLC chromatogram of N-Acetyl-[4-(5-oxy-ethylvalerate)benzyl]-L-
phenylalanine (Cmp. No. 2). 
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 +EMS: 15.642 min from Sample 2 (Meo) of DataSET1.wiff (Turbo Spray) Max. 3.6e7 cps.
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Figure 67. Mass spectrum of N-Acetyl-[4-methoxylbenzyl]-L-phenylalanine (Cmp. 
No. 3). 
 
 
Figure 68. HPLC chromatogram of N-Acetyl-[4-methoxylbenzyl]-L-phenylalanine 
(Cmp. No. 3). 
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 +EMS: 16.033 min from Sample 4 (Me Meo) of DataSET1.wiff (Turbo Spray) Max. 3.9e7 cps.
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Figure 69. Mass spectrum of N-Acetyl-[2-methyl-4-methoxylbenzyl]-L-phenylalanine 
(Cmp. No. 4). 
 
 
Figure 70. HPLC chromatogram of N-Acetyl-[2-methyl-4-methoxylbenzyl]-L-
phenylalanine (Cmp. No. 4). 
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 +EMS: 15.866 min from Sample 2 (77-78) of DataSET1.wiff (Turbo Spray) Max. 9.2e6 cps.
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Figure 71. Mass spectrum of N-Acetyl-[2-methyl-4-(5-oxy-ethylvalerate)benzyl]-L- 
phenylalanine (Cmp. No. 5). 
 
 
Figure 72. HPLC chromatogram of N-Acetyl-[2-methyl-4-(5-oxy-
ethylvalerate)benzyl]-L-phenylalanine (Cmp. No. 5). 
 154 
 
 +EMS: 14.748 min from Sample 4 (45) of DataSET1.wiff (Turbo Spray) Max. 6.5e7 cps.
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Figure 73. Mass spectrum of N-Acetyl-[2,6-dimethyl-4-(5-oxy-
methylbutyrate)benzyl]-L-phenylalanine (Cmp. No. 6). 
 
 
Figure 74. HPLC chromatogram of N-Acetyl-[2,6-dimethyl-4-(5-oxy-
methylbutyrate)benzyl]-L-phenylalanine (Cmp. No. 6). 
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 +EMS: 15.922 min from Sample 8 (50 ) of DataSET1.wiff (Turbo Spray) Max. 2.1e7 cps.
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Figure 75. Mass spectrum of N-Acetyl-[2,6-dimethyl-4-(5-oxy-ethylvalerate)benzyl]-
L-phenylalanine (Cmp. No. 7). 
 
 
Figure 76. HPLC chromatogram of N-Acetyl-[2,6-dimethyl-4-(5-oxy-
ethylvalerate)benzyl]-L-phenylalanine (Cmp. No. 7). 
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 +EMS: 15.531 min from Sample 2 (45-55) of DataSET1.wiff (Turbo Spray) Max. 3.1e7 cps.
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Figure 77. Mass spectrum of N-Acetyl-[2-methoxy-4-(5-oxy-methylbutyrate)benzyl]-
L-phenylalanine (Cmp. No. 8). 
 
 
Figure 78. HPLC chromatogram of N-Acetyl-[2-methoxy-4-(5-oxy-
methylbutyrate)benzyl]-L-phenylalanine (Cmp. No. 8). 
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 +EMS: 15.922 min from Sample 8 (50 ) of DataSET1.wiff (Turbo Spray) Max. 2.1e7 cps.
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Figure 79. Mass spectrum of N-Acetyl-[2-methoxy-4-(5-oxy-ethylvalerate)benzyl]-L-
phenylalanine (Cmp. No. 9). 
 
 
Figure 80. HPLC chromatogram of N-Acetyl-[2-methoxy-4-(5-oxy-
ethylvalerate)benzyl]-L-phenylalanine (Cmp. No. 9). 
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 +EMS: 15.698 min from Sample 3 (DiMeo) of DataSET1.wiff (Turbo Spray) Max. 2.6e7 cps.
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Figure 81. Mass spectrum of N-Acetyl-[2-methoxy-4-methoxylbenzyl]-L-
phenylalanine (Cmp. No. 10). 
 
 
Figure 82. HPLC chromatogram of N-Acetyl-[2-methoxy-4-methoxylbenzyl]-L-
phenylalanine (Cmp. No. 10). 
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 +EMS: 14.748 min from Sample 4 (45) of DataSET1.wiff (Turbo Spray) Max. 6.5e7 cps.
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Figure 83. Mass spectrum of N-Acetyl-[2,6-dimethoxy-4-(5-oxy-
methylbutyrate)benzyl]-L-phenylalanine (Cmp. No. 11). 
 
 
Figure 84. HPLC chromatogram of N-Acetyl-[2,6-dimethoxy-4-(5-oxy-
methylbutyrate)benzyl]-L-phenylalanine (Cmp. No. 11). 
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Figure 85. Mass spectrum of N-Acetyl-[2,6-dimethoxy-4-(5-oxy-ethylvalerate)benzyl]-
L-phenylalanine (Cmp. No. 12). 
 
 
Figure 86. HPLC chromatogram of N-Acetyl-[2,6-dimethoxy-4-(5-oxy-
ethylvalerate)benzyl]-L-phenylalanine (Cmp. No. 12). 
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Figure 87. Mass spectrum of N-Acetyl-[4-(5-oxy-methylbutyrate)naphthyl]-L-
phenylalanine (Cmp. No. 13). 
 
 
Figure 88. HPLC chromatogram of N-Acetyl-[4-(5-oxy-methylbutyrate)naphthyl]-L-
phenylalanine (Cmp. No. 13). 
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Figure 89. Mass spectrum of N-Acetyl-[4-(5-oxy-ethylvalerate)naphthyl]-L-
phenylalanine (Cmp. No. 14). 
 
 
Figure 90. HPLC chromatogram of N-Acetyl-[4-(5-oxy-ethylvalerate)naphthyl]-L-
phenylalanine (Cmp. No. 14). 
 163 
 
 
Figure 91. Mass spectrum of Ac-Phe-Ala-Gly. 
 
 
Figure 92. HPLC chromatogram of Ac-Phe-Ala-Gly. 
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Figure 93. Mass spectrum of Ac-Phe-Leu-Val. 
 
 
Figure 94. HPLC chromatogram of Ac-Phe-Leu-Val.
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Figure 95. Mass spectrum of Ac-Phe-Ala-Gly. 
 
 
Figure 96. HPLC chromatogram of Ac-Phe-Ala-Gly.
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Figure 97. Mass spectrum of Benzoyl-Phe. 
 
Figure 98. HPLC chromatogram of Benzoyl-Phe. 
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Figure 99. Mass spectrum of Tolyoyl-Phe. 
 
 
 
Figure 100. HPLC chromatogram of Tolyoyl-Phe. 
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Figure 101. Mass spectrum of Ac-Phe. 
 
 
Figure 102. HPLC chromatogram of Ac-Phe. 
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Figure 103. Mass spectrum of Isovaleryl -Phe. 
 
Figure 104. HPLC chromatogram of Isovaleryl -Phe. 
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SUMMARY 
In the first part of dissertation, D-boroAla was identified and characterized as 
an antibacterial agent. D-boroAla has activity against both Gram-positive and Gram-
negative organisms, with minimal inhibitory concentrations down to 8 μg / mL. A 
structure-function study on the alkyl side chain revealed that D-boroAla is the most 
effective agent in a series including boroGly, D-boroHomoAla, and D-boroVal. L-
boroAla was much less active, and N-acetylation completely abolished activity. An 
LC-MS / MS assay was used to demonstrate that D-boroAla exerts its antibacterial 
activity by inhibition of D-Ala-D-Ala ligase. D-boroAla is bactericidal at 1x minimal 
inhibitory concentration against Staphylococcus aureus and Bacillus subtilis, which 
each encode one copy of D-Ala-D-Ala, and at 4x minimal inhibitory concentration 
against Escherichia coli and Salmonella enterica serovar Typhimurium, which each 
encode two copies of D-Ala-D-Ala ligase. D-boroAla demonstrated a frequency of 
resistance of 8 × 10-8 at 4x minimal inhibitory concentration in S. aureus. These 
results demonstrate that D-boroAla has promising antibacterial activity and could 
serve as the lead agent in a new class of D-Ala-D-Ala ligase targeted antibacterial 
agents. This study also demonstrates D-boroAla as a possible probe for D-Ala-D-Ala 
ligase function. 
Vancomycin exerts its antibacterial activity by binding to D-Ala-D-Ala in 
bacterial cell wall precursors. Vancomycin resistance in vancomycin-resistant 
enterococci (VRE) is due to an alternative cell wall biosynthesis pathway in which D-
Ala-D-Ala is replaced, most commonly by D-Ala-D-Lac. In the middle part of 
dissertation, we extend our recently developed Marfey's derivatization-based liquid 
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chromatography-tandem mass spectrometry (LC-MS/MS) assay for L-Ala, D-Ala, and 
D-Ala-D-Ala to D-Ala-D-Lac and apply it to the quantitation of these metabolites in 
VRE. The first step in this effort was the development of an effective washing 
method for removing medium components from VRE cells. Mar-D-Ala-D-Lac was 
well resolved chromatographically from Mar-D-Ala-D-Ala, a prerequisite for MS/MS 
quantitation of D-Ala-D-Ala and D-Ala-D-Lac. Mar- D-Ala-D-Lac gave similar detection 
parameters, sensitivity, and linearity as Mar-D-Ala-D-Ala. L-Ala, D-Ala, D-Ala-D-Ala, 
and D-Ala-D-Lac levels in VRE were then determined in the presence of variable 
vancomycin levels. Exposure to vancomycin resulted in a dramatic reduction of D-
Ala-D-Ala, with a response midpoint at approximately 0.06 μg/ml vancomycin and 
with a broad response profile up to 128 μg/ml vancomycin. In contrast, D-Ala-D-Lac 
was present in the absence of vancomycin, with its level constant up to 128 μg/ml 
vancomycin. This method will be useful for the discovery, characterization, and 
refinement of agents targeting vancomycin resistance in VRE. 
Peptide-based agens are of considerable interest as bioactive agents and 
drugs. Considerable research has been done to synthesize peptides and peptide 
memetics using classical solid-phase peptide synthesis (SPPS) in the C-to-N 
direction. However, this strategy is not generally useful for preparing C-terminally 
modified peptide derivatives. On the other hand, SPPS in the N-to-C direction 
(Inverse SPPS) would provide the synthetically versatile C-terminal carboxyl group 
for further elaboration. In the last part of the dissertation, several benzaldehyde 
linkers were studied for use in this applicaiton. Using model reactions, rate constants 
of all the linkers were determined and the reaction constant rho was determined as -
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1.1. The linker with right stability i.e. stable to 25% TFA/DCM treatment for 30 min. 
and should be able cleave the peptide with treatment by 5% HBr/TFA was selected 
2-methyl-4-(5-oxy-ethylvalerate)benzaldehyde and backbone amide linker (BAL) 
strategy for use with amino acid t-butyl ester based ISPPS was developed. The 
stability of the linker was demonstrated by synthesizing and characterization of 
several acetyl capped peptides. This approach provided acetyl capped peptides in 
high yield and purity, without detectable levels of racemization. However, an effort to 
use this and similar linkers for Bidirection SPPS was unsuccessful, since the linker 
with suitable acid stability for OtBu deprotection were unreactive for amino acid 
acylation of the secondary amine intermediate.This approach will be helpful in 
synthesizing several peptide memetic classes by using already available starting 
materials. This approach is also suited for use with combinatorial chemistry based 
startegies for drug and bioactive agents discovery and optimization. 
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